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Abstract
Fruit juice-drug interactions (FJDIs) involving non-metabolized oral medications result in
decreased drug exposure that may lead to reduced therapeutic efficacy. The effect is thought
to be mediated by inhibition of the intestinal drug transporters organic anion transporting
polypeptide 1A2 and 2B1 (OATP1A2 and OATP2B1) by fruit juice constituents, however
the exact mechanisms remain controversial. We tested the hypothesis that fruit juices limit
the absorption of fexofenadine through interactions with specific intestinal transporters. In
vitro transport and fruit juice inhibition studies using fexofenadine, a medication involved in
FJDIs, revealed that in addition to previously implicated transporters, organic cation
transporter 1 (OCT1) and organic solute transporter alpha/beta (OSTα/β) are potential novel
targets of fruit juice components. Pharmacokinetic interaction studies in wild-type and
mOatp2b1 knockout mice demonstrated that mOatp2b1 is not involved in fexofenadine
absorption or FJDIs in vivo. These findings provide new insights into the mechanism of
FJDIs.
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1 Introduction
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1.1

Adverse Drug Events

Patient safety during drug treatment has become a top priority for health care systems
worldwide. Adverse drug events (ADEs), defined as unwanted effects due to the use or
misuse of medications, are an important cause of patient harm and suboptimal therapy
(Baker et al., 2004; Nebeker et al., 2004). Alarmingly, ADEs happen virtually on a daily
basis in hospitals and the community (Nebeker et al., 2004). Such events may result in
increased doctor visits, longer hospital stays, reduced quality of life and even death
(Baker et al., 2004). Lazarous et al., (1998) reported that approximately 6.7% of all
hospitalized patients experience a serious adverse drug reaction. Of particular concern is
that these reactions have risen to become the fourth leading cause of death (Lazarou et
al., 1998). Not only do ADEs pose additional patient health risks and impede effective
disease management, they also constitute a substantial economic burden on the Canadian
health care system. During the 2010-2011 period, 1 in 200 seniors was hospitalized for an
adverse drug reaction (https://www.cihi.ca/en). In 2008 alone, it was estimated that ADEs
occurring in hospitals cost approximately $5.6 billion (Hohl et al., 2011). It should be
noted that a staggering 37-51% of ADEs are avoidable (Baker et al., 2004).

1.2

Drug Interactions

A major cause of ADEs are drug interactions which are common and in many cases,
preventable (Roughead et al., 2010). Drug interactions can be defined as changes in the
effect of an administered drug when it is taken together with another drug or dietary
substance or with specific disease states (http://www.fda.gov). This occurrence can result
in increased or decreased therapeutic activity of a medication, or lead to unanticipated
side effects (http://www.fda.gov). While it is often considered that drug interactions can
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cause harm, it is necessary to consider that in some therapeutic contexts, drug interactions
are intended. The true incidence of unintended drug interactions in the population is
difficult to quantify. Some reasons for the lack of such statistics include the notion that
only 1 in 20 ADEs are ever reported and that ADEs are less commonly captured in noninstitutional settings (Hazell and Shakir, 2006). Importantly, ADEs that result in loss of
drug efficacy such as certain fruit juice-drug interactions, which form the subject of this
thesis, are rarely identified and reported.

1.2.1

Pharmacokinetic and Pharmacodynamic Mechanisms of
Drug Interactions

Pharmacokinetics is the study of drug concentrations in various body compartments as a
function of time. This area of pharmacology also examines how the body processes a
medication. Consequently, pharmacokinetic drug interactions can be defined as those
which occur when an illness or co-consumed substance alters drug disposition by
changing a drug’s absorption into circulation, its distribution into tissues, its metabolism
by enzymes into polar compounds, or its excretion out of the body, generally via urine or
feces (Buxton and Benet, 2011). Drug interactions of this nature will ultimately affect the
concentration or duration of medications at their site of action and the associated
therapeutic or toxic responses.
Pharmacodynamics on the other hand, links drug concentration at the site of action with
the degree of therapeutic effect elicited (Blumenthal and Garrison, 2011). This branch of
pharmacology is focused on the cellular targets of medications, commonly, receptors
(Blumenthal and Garrison, 2011). Therefore, pharmacodynamic drug interactions
typically arise when another substance or pre-existing disorder alters the receptor
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signalling pathway affected by the drug, resulting in synergistic, antagonistic or novel
responses. Generally, greater clinical effects of drugs are associated with increasing drug
concentrations at the target site.

1.2.2

Types and Clinical Consequences of Drug Interactions

Drug interactions can compromise the safe and effective use of medicinal agents. There
are 4 main types of drug interactions, namely, drug-drug, herb-drug, disease-drug and
food-drug interactions (http://www.fda.gov). Examples of each category and the clinical
consequences associated are found in Table 1.1. Despite the fact that the many
mechanisms are well-characterized, in clinical practice, it is often difficult to recognize
potential drug interactions, making them hard to avoid. The prevalence of polypharmacy
and individuals presenting with comorbidities, especially in the elderly patient
population, mean that drug-drug and disease-drug interactions occur frequently (Maher et
al., 2014). It therefore becomes easy to miss possible interactions when prescribing
medications. Indeed, a recent population-based study estimated that 15% of older adults
are at risk for a major drug-drug interaction (Qato et al., 2016). Furthermore, herbs, other
natural products and dietary supplements are regularly used but are often considered safe
and frequently overlooked as substances that may impact drug activity (Hussain, 2011).
As such, patients fail to mention these products to their physicians and similarly,
physicians often do not consider these remedies as possible contraindications to
prescription medications. Co-ingestion of oral medications with food is commonly used
as a tool to improve patient adherence to drug therapy, but at the potential risk of
increasing the probability of food-drug interactions (Marek and Antle, 2008). Because
diets are complex and have only recently been considered as mediators of drug

5

interactions, the mechanisms underlying most food-drug effects have not been fully
explored. A better understanding of the mechanisms mediating food-drug interactions can
aid in the implementation of practical strategies to avoid ADEs and improve
pharmacotherapy management. The focus of this thesis is on food-drug interactions, in
particular those involving fruit juices.
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Table 1.1 Examples of clinically relevant drug interactions.
Type of Drug
Interaction
Drug-Drug

Drug
Warfarin

Interacting
Clinical
Substance/Disease Consequence
Amiodarone
Increase
bleeding risk
Chronic kidney
Neutropenia
disease

Disease-Drug

Methotrexate

Herb-Drug

Cyclosporine

St. John’s Wort

Organ
transplant
rejection

Food-Drug

Felodipine

Grapefruit juice

Hypotension

Reference
Heimark et al.
(1992)
Ellman and
Ginsberg
(1990);
Chatham et al.
(2000)
Ruschitzka et
al. (2000);
Breidenbach et
al. (2000)
Bailey et al.
(1989); Bailey
et al. (1991)
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1.3
1.3.1

Fruit Juice-Drug Interaction (FJDI)
Discovery

One third of Canadians drink fruit juices on a daily basis (http://www.statcan.gc.ca). This
statistic is concerning from a therapeutic point of view as fruit juices are now welldocumented components of the diet that are involved in food-drug interactions. The
effect was serendipitously discovered by Bailey et al. (1989) during an interaction study
between ethanol and felodipine, an oral antihypertensive, in which grapefruit juice (GFJ)
was used to mask the flavor of ethanol. Interestingly, the co-ingestion of GFJ with
felodipine in both the control and experimental groups resulted in a clinically significant
rise in plasma drug levels in comparison to previously reported values (Bailey et al.,
1989). This prompted a follow-up study where volunteers were administered felodipine
with and without GFJ (Bailey et al., 1991). In this study, co-administration with the fruit
juice led to a 3-fold increase in the area under the plasma drug concentration vs. time
curve (AUC), a reflection of systemic drug exposure, which was presumed to result from
increased felodipine oral bioavailability rather than reduced systemic clearance (Bailey et
al., 1991). Oral bioavailability refers to the fraction of an orally administered dose that
makes it into systemic circulation unchanged, following absorption across the
gastrointestinal wall and metabolism by gut and hepatic enzymes, to become
therapeutically available. The dramatic rise in plasma felodipine levels led to an
exacerbation of its clinical effect (greater drop in diastolic blood pressure) and increased
the incidence of adverse side effects (more frequent headaches) (Bailey et al., 1991).

1.3.2

Drug Metabolizing Enzyme-Mediated Mechanisms

Since the initial discovery, the effect of GFJ on the pharmacokinetics of numerous other
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drugs have been evaluated. Clinically relevant interactions have been identified across
numerous drug classes including calcium channel blockers, protease inhibitors, statins
and immunosuppressants such as nifedipine, saquinavir, atorvastatin and cyclosporine,
respectively (Bailey et al., 1991; Ducharme et al., 1995; James, 1995; Yee et al., 1995;
Reddy et al., 2011).
Many GFJ-drug interactions involve medications that are substrates of cytochrome P450
3A4 (CYP3A4), an enzyme responsible for the intestinal and hepatic oxidative
metabolism of xenobiotic compounds. In most cases, increased drug bioavailability with
GFJ co-consumption was only seen when the therapeutic compound was given orally, but
not intravenously. Furthermore, the time required for the plasma drug concentration to
decline by one half, the half life (t1/2), is generally not affected by grapefruit juice intake.
Together, these findings suggested that GFJ caused specific inhibition of CYP3A4 that
occurred at the level of the intestine. Moreover, it would appear that GFJ does not have
an inhibitory effect on the metabolic activity of hepatic CYP3A4 as reflected by the lack
of change to t1/2 and systemic clearance.
In support of this mechanism, Lown et al. (1997) demonstrated using small bowel
biopsies that GFJ ingestion for 6 days resulted in a 62% decrease in enterocyte CYP3A4
protein concentration. The effect was observed as early as 4 hours post juice
administration (Lown et al., 1997). Interestingly, CYP3A4 messenger ribonucleic acid
(mRNA) levels in intestinal epithelial cells were unchanged with GFJ consumption
(Lown et al., 1997). Thus, GFJ appeared to impact the enzyme post-transcriptionally,
through a mechanism involving rapid CYP3A4 protein degradation. Studies by Edwards
et al. (1996) and Schmiedlin-Ren et al. (1997) reinforced this idea by showing that
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specific components of GFJ known as furanocoumarins are mechanism-based
inactivators of CYP3A4 in vitro. A key GFJ furanocoumarin, bergamottin, was found to
be metabolized to 6’7-dihydroxybergamottin (DHB), a suicide inhibitor of intestinal
CYP3A4 (Lin et al., 2012). Duration of the GFJ effect was dependent on the de novo
synthesis rate of the CYP3A4 enzyme and the natural turnover of intestinal enterocytes.
The intestinal specificity of this metabolic interaction was confirmed in a study that
showed hepatic CYP3A4 activity, as determined by erythromycin breath tests, was
unaffected by GFJ (Lown et al., 1997). This finding implies that liver exposure to GFJ
furanocoumarins is limited.

1.3.3

Non-Metabolic FJDIs

With subsequent studies, it has become increasingly evident that fruit juice-mediated
effects on drug disposition cannot be attributed solely to inhibition of metabolism. The
pharmacokinetics of numerous minimally-metabolized drugs have also shown to be
influenced by GFJ co-ingestion (Table 1.2). Intriguingly, reductions in oral
bioavailability and plasma concentrations are seen for some non-metabolized drugs when
taken with GFJ which contrasts with increased systemic drug concentrations for
CYP3A4-metabolized medications. The duration of GFJ effects was another difference
observed for interactions with non-metabolized drugs. Due to the requirement for de novo
CYP3A4 synthesis after GFJ exposure, the bioavailability of metabolized drugs
administered is significantly impacted up to 26 hours post juice intake (Lundahl et al.,
1995; Greenblatt et al., 2003). However, with non-metabolized medications, the effect of
GFJ on drug disposition dissipated within 2-4 hours after juice administration (Glaeser et
al., 2007). Furthermore, apple juice (AJ) and orange juice (OJ) elicit minimal changes to
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the pharmacokinetics of CYP3A4 substrate drugs. On the other hand, these juices reduce
the systemic exposure of minimally-metabolized therapeutic agents to a degree similar to
that observed with GFJ (Dresser et al., 2002). Therefore, it would appear that there are
drug metabolizing enzyme-independent mechanisms involved in certain FJDIs, perhaps
related to modulation of membrane drug transport. Moreover, the specific constituents in
fruit juices that affect the pharmacokinetics of non-metabolized drugs may differ from the
furanocoumarins implicated in metabolic GFJ interactions.
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Table 1.2 Clinical effects of grapefruit juice (GFJ) and apple juice (AJ) on oral drug
bioavailability that cannot be explained by changes in drug metabolism.

Juice

Effect on Oral
Bioavailability
(Compared to Water)

GFJ

Decrease

AJ

Decrease

GFJ
GFJ

Decrease
Decrease

AJ

Decrease

Atenolol
Celiprolol

AJ
GFJ

Decrease
Decrease

Digoxin

GFJ

Increase*

Talinolol

GFJ

Decrease

Chemotherapy Drug
Etoposide

GFJ

Decrease

Reif et al. (2002)

Hormone
Levothyroxine

GFJ

Decrease

Lilja et al. (2005a)

Drug
Antihistamine
Fexofenadine

Cardiovascular Drugs
Acebutolol
Aliskiren

Reference
Banfield et al.
(2002); Dresser et al.
(2002); Dresser et al.
(2005); Bailey et al.
(2007); Glaeser et al.
(2007); Won et al.
(2013)
Dresser et al. (2002);
Imanaga et al.
(2011); Akamine et
al. (2014)
Lilja et al. (2005b)
Tapaninen et al.
(2010); Rebello et
al. (2012)
Tapaninen et al.
(2011)
Jeon et al. (2013)
Lilja et al. (2003);
Ieiri et al. (2012)
Becquemont et al.
(2001)
Schwarz et al.
(2005)

*Effect was significant between 0-24 hours post drug administration. Effect was not
significant between 0-48 hours post drug administration.
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1.4

Fexofenadine, a Prototypical Non-Metabolized
Drug That is Subject to FJDIs

Fexofenadine, commonly known by its trade name Allegra, is a second generation H1
histamine receptor antagonist used for the treatment of seasonal allergies and chronic
hives (Smith and Gums, 2009). Available as oral fexofenadine hydrochloride tablets, the
typical doses for adults are 60 mg twice daily or 180 mg once daily
(http://products.sanofi.ca). Following oral administration, fexofenadine exists as a
zwitterion during transit through the small and large bowel (Chen, 2007) (Figure 1.1).
Indeed, it is categorized as a Class III drug under the Food and Drug Administration
biopharmaceutical classification system, meaning that it has high water solubility and low
membrane permeability. Hence, oral fexofenadine absorption from the gut lumen is
presumed to be mediated not by passive diffusion but by the opposing activities of
intestinal uptake and efflux transporters located in the apical membrane of the gut
mucosa (Chen, 2007). The antihistamine is absorbed relatively quickly into circulation as
the time needed to reach peak plasma concentration (Tmax) occurs between 1-3 hours after
administration (Smith and Gums, 2009). Fexofenadine undergoes minimal breakdown by
metabolic enzymes such as CYP3A4 and is mainly eliminated unchanged in the urine
(10%) and feces (80%) (Smith and Gums, 2009). Bioavailability has been estimated to be
approximately 33% for the oral dose (Smith and Gums, 2009). As fexofenadine
experiences negligible metabolism, the oral bioavailability, tissue distribution and
clearance is largely dependent on the activity of drug transporters in the gut, liver and
kidney. For this reason, fexofenadine has been administered to study subjects as a “probe
drug” to assess the in vivo transport activity of solute carrier proteins (Flynn et al., 2011).
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Figure 1.1 Chemical structure of fexofenadine.
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1.5

Role of Intestinal Transporters in Fexofenadine and
Other FJDIs

In 2002, Dresser et al. demonstrated the first example of a FJDI whose mechanism was
independent of CYP enzymes. In that seminal report, fexofenadine was co-administered
with 1.2 L of GFJ, AJ or water over 3 hours to a cohort of healthy volunteers.
Interestingly, concomitant ingestion of either fruit juice reduced plasma drug exposure to
23-33% of that with water (Dresser et al., 2002). Fexofenadine renal clearance and t1/2
were not affected by the fruit juices, suggesting minimal impact of juices on excretory
organs such as the liver and kidney and localizing the interaction to the site of drug
absorption (Dresser et al., 2002). A similar finding was reported by Banfield and
colleagues (2002) when they administered fexofenadine to subjects who consumed 240
mL of double-strength GFJ, 3 times daily for 2 days prior to, during and 2 hours after
drug administration. Given the unusual amount of GFJ consumed in these early studies,
the clinical relevance of the GFJ-fexofenadine interaction was demonstrated in a
subsequent study involving co-administration of drug with a more reasonable volume
(300 mL) of GFJ (Dresser et al., 2005).
As eluded to previously, the effect of GFJ on plasma fexofenadine exposure was shortlived as no reduction in AUC was observed when GFJ was administered 4 hours prior to
fexofenadine intake (Glaeser et al., 2007). Additionally, unlike enzyme-mediated FJDIs,
other components of fruit juices known as flavonoids, not furanocoumarins, were
considered probable players of this interaction (will be discussed in further detail in
Section 1.9). This was compellingly demonstrated when naringin, a major flavonoid
found in GFJ, was orally administered at concentrations equivalent (1200 µM, 300 mL)
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to that found in GFJ, together with fexofenadine, plasma drug levels were reduced
significantly but not to the same extent as with GFJ (Bailey et al., 2007). Furthermore,
modified GFJ lacking furanocoumarins (commercially produced to minimize metabolic
drug interactions) elicited the same change to fexofenadine AUC as regular GFJ (Won et
al., 2013).
Since these initial reports with fexofenadine, other non-metabolized medications across
several drug classes have been shown to be affected by fruit juices (Table 1.2).
Generally, there is decreased systemic drug exposure for these oral medications when
given with juices. Such interactions are expected to result in reduced clinical effects,
subjecting patients to suboptimal disease treatment and/or management.
Given the common pharmacokinetic effect of fruit juices on the oral absorption of many
non-metabolized drugs, it is generally considered that the mechanism of these food-drug
interactions involves modulation of intestinal drug transporters. Indeed, a number of
intestinal drug transporters that are responsible for facilitating or impeding drug
absorption have become proposed targets for fruit juice-drug interactions. At present
however, the exact transporters involved and the molecular mechanisms still remain
unclear owing to the lack of compelling data from in vitro and preclinical models that are
all consistent with the clinical observations. Ideally, the mechanisms for clinical FJDIs
for non-metabolized drugs will be firmly established by in vitro studies that demonstrate
that the affected drug is a transport substrate of a membrane transporter known to be
expressed in the human intestine. Furthermore, in vitro studies should show that drug
transport by these membrane proteins is inhibited or stimulated by fruit juices and their
specific constituents. In conjunction with in vitro studies, mechanisms for FJDIs will be
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persuasively established in experiments with animal models, including transporter
knockout (KO) mice, that will shed additional in vivo insights to explain the clinical
problem.

1.6
1.6.1

Intestinal Apical Uptake Transporters
Potential Mechanistic Role in FJDI

The oral absorption of hydrophilic and charged drugs such as fexofenadine are less likely
to result from passive diffusion mechanisms but are largely dependent on the actions of
drug transporters localized on the apical (luminal) and basolateral membranes of
intestinal enterocytes. Vectorial movement of fexofenadine across the enterocyte would
require uptake transport on the apical membrane coupled with efflux transport on the
basolateral membrane for entry into the portal circulation. Inhibition of uptake
transporters located on the apical membrane of intestinal epithelial cells is the leading
mechanism that would be consistent with the observed reduction of fexofenadine
bioavailability by juices. A number of drug uptake transporters are expressed on the
enterocyte apical membrane including those in the organic anion transporting polypeptide
(OATP), organic cation transporter (OCT, OCTN), peptide transporter (PEPT), bile acid
and heme transporter families of solute carriers (Figure 1.2). A few of these transporters
are already known to facilitate fexofenadine cellular uptake in vitro, however the entire
complement of relevant intestinal transporters has not been established. Moreover, in
vitro studies have demonstrated that some of these transporters are inhibited by fruit
juices or their constituents.
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Figure 1.2 Potential intestinal uptake transporters involved in fruit juice-drug interactions
in humans and in mice. *Confirmed and ?controversial localization to the apical
membrane of enterocytes.
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1.6.2

Organic Anion-Transporting Polypeptides (OATPs)

Organic anion-transporting polypeptides (OATPs) are a superfamily of integral
membrane uptake transporters belonging to the solute carrier organic anion (SLCO) gene
superfamily (Hagenbuch and Meier, 2003). They are responsible for the sodiumindependent cellular influx of a wide spectrum of cationic, neutral and anionic
compounds (Hagenbuch and Meier, 2003). These solute carriers facilitate the movement
of endogenous molecules including bilirubin, bile acids, prostaglandins, thyroid and
steroid hormones throughout the body (Tirona and Kim, 2014). Moreover, OATPs have
been shown to transport several clinically relevant xenobiotics including antihistamines,
beta blockers, statins and antidiabetic agents (Dresser et al., 2002; Satoh et al., 2005; Ho
et al., 2006; Ieiri et al., 2012). OATP transport activity typically favors a low pH
environment and is mediated by exchange with intracellular compounds such as
bicarbonate and glutathione (Nozawa et al., 2004; Meier-Abt et al., 2005; Leuthold et al.,
2009; Eechoute et al., 2011). Some OATPs are ubiquitously expressed while others are
tissue-selective (Tirona and Kim, 2014). Additionally, OATP cellular expression is
commonly polarized to either the apical or basolateral membranes, depending on the
tissue epithelium (Tirona and Kim, 2014). Notably, OATP1A2 and OATP2B1 are two
isoforms found in the luminal membrane of human small bowel epithelial cells
(Kobayashi et al., 2003; Glaeser et al., 2007). Numerous substrate drugs, such as
fexofenadine are thought to rely on the transport activity of these two OATPs for
absorption (Tamai and Nakanishi, 2013). For these reasons, OATP1A2 and OATP2B1
have been the principal suspect transporters involved in FJDIs.
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1.6.2.1

OATP1A2

With the first clinical demonstration of the fruit juice-fexofenadine interaction,
OATP1A2 was proposed to be the primary culprit (Dresser et al., 2002). In support of
this claim, in vitro studies performed by Dresser et al. (2002) reconfirmed that
fexofenadine was a substrate of OATP1A2 (Cvetkovic et al., 1999). Importantly, GFJ, AJ
and the juice flavonoids naringin and hesperidin, at relevant concentrations, limited
uptake of the antihistamine by OATP1A2 in cellular models (Dresser et al., 2002; Bailey
et al., 2007). Remarkably however, it was not known in 2002 whether OATP1A2 is
expressed in the intestine. In a follow-up study by the same research group, the mRNA
expression of various transporters was determined in human duodenal biopsies.
OATP1A2 transcript, among other uptake transport proteins, was detected consistently in
small bowel mucosa (Glaeser et al., 2007). Subsequent immunohistochemical and
immunofluorescent staining supported OATP1A2 localization to the apical membrane of
enterocytes (Glaeser et al., 2007). Its prominent role in the fruit juice interaction was
further emphasized after an in vitro screen of transport proteins identified OATP1A2 as
the only intestinally-expressed uptake transporter capable of mediating significant
fexofenadine cellular influx (Glaeser et al., 2007). Moreover, in line with the short-lived
effect of GFJ on fexofenadine plasma concentration, intestinal OATP1A2 mRNA and
protein levels were not affected by juice exposure (Glaeser et al., 2007).
Although these findings had strongly implicated OATP1A2 in FJDIs, its mechanistic role
in vivo remains highly debated, as controversy surrounds whether the transporter is
expressed in the small intestine at all. While numerous research groups have detected
levels of OATP1A2 mRNA and protein in the gut (Su et al., 2004; Ballestero et al., 2006;
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Glaeser et al., 2007; Maubon et al., 2007), there is equal evidence demonstrating limited
or absent expression of both transcript and protein at the site of fexofenadine absorption
(Nishimura and Naito, 2005; Hilgendorf et al., 2007; Meier et al., 2007; Eechoute et al.,
2011; Drozdzik et al., 2014). Therefore, current focus has shifted to another OATP
isoform as the main facilitator of the fruit juice-fexofenadine effect.

1.6.2.2

OATP2B1

There has been increasing support for the role of OATP2B1 in transporter-mediated
FJDIs. Unlike OATP1A2, its expression in the small intestine is well documented and
undisputed, as high levels of both mRNA and protein have been consistently reported in
the literature (Kobayashi et al., 2003; Nishimura and Naito, 2005; Meier et al., 2007;
Drozdzik et al., 2014). Although Glaeser et al. (2007) detected OATP2B1 mRNA
transcript in duodenal biopsies, their original in vitro evaluation did not demonstrate
fexofenadine transport by this solute carrier. Since then however, there have been several
accounts of OATP2B1-mediated fexofenadine uptake in other cellular models,
solidifying fexofenadine as a now well-accepted substrate of the transporter (Nozawa et
al., 2004; Imanaga et al., 2011; Shirasaka et al., 2011; Shirasaka et al., 2013b; Akamine
et al., 2014; Akamine, 2015). Similar to OATP1A2, fexofenadine co-incubation with GFJ
and AJ significantly reduced its cellular influx by OATP2B1 in vitro (Imanaga et al.,
2011; Shirasaka et al., 2013b). While flavonoid inhibition of OATP2B1 transport activity
of various drugs have been demonstrated, specific attenuation of fexofenadine transport
by these fruit juice components has not yet been reported in OATP2B1 cellular
expression systems (Shirasaka et al., 2013a).
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In contrast to OATP1A2, there is some in vivo support for the role of OATP2B1 in
FJDIs. The SLCO2B1 c.1457C>T genetic polymorphism is associated with reduced
OATP2B1 transport function in vitro (Nozawa et al., 2002). Interestingly, individuals
harboring this allele displayed lower fexofenadine plasma exposure than wild-type (WT)
volunteers (Imanaga et al., 2011). Moreover, although AJ diminished fexofenadine AUC
in both WT and c.1457C>T allele carriers, the effect was less pronounced in those
carrying SLCO2B1 variant alleles (Imanaga et al., 2011). Therefore, it would appear that
fexofenadine is an in vivo substrate of OATP2B1 and that AJ may act on this drug
transporter as a functional inhibitor.

1.6.2.3

Mouse Orthologs of OATPs

There are 4 mouse orthologs of human OATP1A2, namely mOatp1a1, mOatp1a4,
mOatp1a5 and mOatp1a6 (van de Steeg et al., 2010). Interestingly, these 4 transporters
have low to undetectable mRNA expression along the gastrointestinal tract (Cheng et al.,
2005; Fu et al., 2016). Unfortunately, substrate specificities of individual mOatp1a
transporters have not been well characterized, particularly with respect to fexofenadine.
Additionally, in vitro effects of fruit juices on mOatp1a transporters have never been
reported.
In contrast to OATP1A2, OATP2B1 is highly conserved between species as a single
orthologous isoform. Approximately 77% of the protein sequence is shared between the
human and the mouse ortholog (Lan et al., 2009). Importantly, mouse Oatp2b1
(mOatp2b1) mRNA has been detected at high levels in the small bowel of mice,
suggesting analogous expression to the human transporter, but protein expression has not
been confirmed experimentally (Cheng et al., 2005; Fu et al., 2016). It is currently known
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whether fexofenadine is a substrate for mOatp2b1 or if it can be inhibited by fruit juices.

1.6.3

Organic Cation Transporters (OCTs)

Organic cation transporter 1 (OCT1), an isoform of the polyspecific transporter proteins
of solute carrier family 22 (SLC22A1), is an uptake protein responsible for the cellular
influx of cationic compounds such as endogenous acetylcholine (Mimura et al., 2015).
Notably, it transports numerous drug substrates including antidiabetic and antiviral
medications (Jonker et al., 2003). This solute carrier was originally localized to the
basolateral membrane of intestinal epithelial cells (Muller et al., 2005). However, more
recent findings have provided evidence to support the expression of OCT1 in the apical
membrane of human enterocytes (Han et al., 2013). In vitro studies have shown the
inhibition of OCT1 transport activity by AJ flavonoids, quercetin and phloretin (Mimura
et al., 2015). However, fexofenadine appears to be a very weak transporter substrate of
OCT1 in vitro (Glaeser et al., 2007).
OCT3 is another isoform found on the apical membrane of enterocytes (Muller et al.,
2005). Similarly, it mediates the absorption of organic cations and has a wide spectrum of
xenobiotic drug substrates. It is not known whether fexofenadine is a substrate of OCT3
or if fruit juices affect transport activity.

1.6.3.1

Mouse Orthologs of OCTs

The mouse ortholog of OCT1 has been localized to the apical membrane of the small
intestine (Han et al., 2013). Mouse Oct1 (mOct1) and human OCT1 possess similar
substrate

specificity.

For

example,

metformin,

an

antidiabetic

drug

and

tetraethylammonium, an experimental compound, are substrates of both transporters
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(Lozano et al., 2013). The mRNA transcript of the mouse ortholog of OCT3 (mOct3) has
been measured at significant levels in the small intestine of mice but its polarized
expression in enterocytes remains unknown (Fu et al., 2016). Fexofenadine transport by
mOct1 and mOct3 and inhibition by fruit juices have not been previously reported.

1.6.4

Other Apical Uptake Transporters

Organic cation/carnitine transporters 1 and 2 (OCTN1 and OCTN2) may also be involved
in FJDIs. They are located in the luminal membrane of intestinal epithelial cells (Lahjouji
et al., 2001; Sugiura et al., 2010). An important endogenous substrate of OCTN
transporters is carnitine, an amino acid derivative involved in lipid metabolism (Lahjouji
et al., 2001). OCTNs also have several drug substrates such as verapamil and
doxorubicin, antihypertensive and chemotherapeutic medications, respectively (Pochini
et al., 2013). Finally, peptide transporter 1 (PEPT1), apical sodium-dependent bile acid
transporter (ASBT) and heme carrier protein 1 (HCP1; SLC46A1) are uptake transporters
found in the luminal membrane of the gut epithelia (Ziegler et al., 2002; Shayeghi et al.,
2005; Balakrishnan and Polli, 2006). Due to the localization of these transporters, they
may also play a role in FJDIs. However, fexofenadine transport ability and the effect of
fruit juices these carrier proteins have not been studied.
The mouse orthologs of OCTN1, OCTN2, PEPT1, ASBT and HCP1 are mOctn1,
mOctn2, mPepT1, mAsbt and mHcp1, respectively. Similarly, they are located in the
luminal membrane of mouse enterocytes (Hakansson et al., 2002; Shayeghi et al., 2005;
Kato et al., 2006; Chen et al., 2010; Sugiura et al., 2010). Again, fexofenadine transport
by these proteins and the effect of fruit juices on their activity are unknown.
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1.7
1.7.1

Intestinal Apical Efflux Transporters
Potential Mechanistic Role in FJDI

Other possible explanations for FJDIs include transport stimulation or gene expression
induction of efflux transporters located on the apical membrane of enterocytes (Figure
1.3). Drugs that traverse the apical membrane of intestinal epithelial cells are pumped
back out into the gut lumen by these transporters, limiting absorption. Increased activity
of efflux transporters would further impede drug absorption and reduce systemic
exposure.
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Figure 1.3 Potential intestinal efflux transporters involved in fruit juice-drug interactions
in humans and in mice. *Confirmed localization to the apical or basolateral membrane of
enterocytes.
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1.7.2

P-Glycoprotein (P-gp)

P-glycoprotein (P-gp), also known as multidrug resistance protein 1 (MDR1), is a
member of the adenosine triphosphate (ATP)-binding cassette superfamily of membranebound efflux transporters (Lin and Yamazaki, 2003). It is recognized for mediating the
cellular exclusion of numerous xenobiotic compounds including but certainly not limited
to, digoxin, a cardiac glycoside, cyclosporine, an immunosuppressant and pertinently,
fexofenadine, an antihistamine (Cvetkovic et al., 1999; Lin and Yamazaki, 2003). P-gp is
expressed in a polarized manner in the epithelial cells of numerous tissues. For example,
it is found in the blood side of brain capillary endothelial cells and apical membrane of
kidney proximal tubule epithelial cells (Lin and Yamazaki, 2003). Importantly, this efflux
transporter is localized to the brush boarder of enterocytes, allowing it to limit the
intestinal absorption of substrate oral medications (Thiebaut et al., 1987; Glaeser et al.,
2007). Indeed, co-administration of P-gp inhibitor drugs such as ketoconazole,
itraconazole and lopinavir/ritonavir increases the plasma concentrations of fexofenadine
in humans (Yasui-Furukori et al., 2005; Shimizu et al., 2006; Uno et al., 2006).
Moreover in humans, inducing intestinal P-gp expression by treatment with the herbal
medication, St. John’s Wort, reduced the bioavailability of fexofenadine (Dresser et al.,
2003). Due to its broad substrate specificity and clear importance in modulating intestinal
drug absorption, the involvement of P-gp in FJDIs must be considered.
Several in vitro studies examining the effect of GFJ and its components on P-gp transport
have led to contradictory findings. For instance, while Soldner et al. (1999) found
stimulation of P-gp transport by GFJ, Takanaga et al. (1998), Honda et al. (2004) and de
Castro et al. (2007) all demonstrated inhibition of P-gp activity by GFJ and/or its
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components. Various other groups have also proposed concentration- and exposure timedependent effects of fruit juices on P-gp mediated efflux (Mitsunaga et al., 2000;
Panchagnula et al., 2005). At present, the evidence favors the inhibitory action of juices
on this efflux transporter.
In the case that P-gp function was impaired clinically, significant efflux transport
inhibition would have led to a rise in plasma fexofenadine exposure. Since oral
bioavailability is attenuated in the fruit juice-fexofenadine interaction, it is commonly
thought that inhibition of uptake transporters contributes more significantly to
fexofenadine plasma drug levels than inhibition of intestinal efflux transport. In support
of this idea, in vitro studies have shown that the GFJ flavonoid, naringin was a more
potent inhibitor of intestinal uptake transporters than P-gp (Dolton et al., 2012).
Furthermore, Dresser et al. (2002) found that while 5% GFJ and AJ significantly
inhibited OATP transport activity, P-gp mediated efflux activity was not altered in
cellular expression models.

1.7.2.1

Mouse Orthologs of P-gp

There are 2 mouse orthologs of human P-gp, namely Mdr1a and Mdr1b. Both
transporters are found in the liver and kidney, while Mdr1a is distinctly expressed in the
luminal membrane of small bowel epithelial cells (Panwala et al., 1998; Lin and
Yamazaki, 2003). Thus, in terms of intestinal absorption, Mdr1a plays a larger role in
drug disposition than Mdr1b. Little information exists on the in vitro transport activity of
Mdr1a. However, in vivo studies in Mdr1a KO mice suggest that fexofenadine is a
substrate of the efflux transporter (Cvetkovic et al., 1999; Tahara et al., 2005). Again, the
effect of fruit juices on Mdr1a function is unknown.
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1.7.3

Other Apical Efflux Transporters

Other apically-localized intestinal efflux transporters exist and their roles in FJDIs should
be investigated. One notable example is the intestinal brush boarder solute carrier,
multidrug resistance-associated protein 2 (MRP2) (Fromm et al., 2000). Fexofenadine is
a substrate of this solute carrier in vitro (Ming et al., 2011). Moreover, much like P-gp,
GFJ has been shown to inhibit MRP2 transport activity in cellular models (Honda et al.,
2004). Finally, components of GFJ and AJ have also been shown to inhibit the transport
activity of another apical efflux transporter, breast cancer resistance protein (BCRP), in
vitro (Fleisher et al., 2015). However, fexofenadine does not appear to be a good
substrate of BCRP as no significant difference in fexofenadine pharmacokinetics was
observed in individuals with a BCRP functional polymorphism (Akamine et al., 2010).
Significant levels of mouse MRP2 (mMrp2) mRNA transcript along the small intestine
have been reported (Fu et al., 2016). The efflux transporter is also expressed in the bile
canalicular membrane of hepatocytes (Kikuchi et al., 2002). Therefore, MRP2 is
considered a key transporter mediating the excretion of xenobiotics into bile and
subsequent elimination in feces. Although its role in the intestinal absorption of
fexofenadine has not been elucidated, the antihistamine appears to be an in vivo substrate
of the transporter based on altered biliary excretion of the drug in mMrp2 KO mice (Tian
et al., 2008). Mouse BCRP (mBcrp) has been confirmed to the apical membrane of gut
epithelial cells (Shimizu et al., 2011). Similar to the human ortholog, fexofenadine does
not appear to be a substrate of mBcrp in vivo (Tian et al., 2008). The impact of fruit
juices on the transport activities of mMrp2 and mBcrp is not known.
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1.8
1.8.1

Intestinal Basolateral Efflux Transporters
Potential Mechanistic Role in FJDI

Fruit juice inhibition of efflux transporters found on the basolateral membrane of
intestinal epithelial cells could also lead to decreased drug exposure (Figure 1.3). These
transporters are responsible for moving intracellular compounds across the basolateral
membrane of enterocytes, into circulation. Inhibition of efflux transporters would prevent
this final step in intestinal absorption.

1.8.2

Organic Solute Transporters Alpha and Beta (OSTα/β)

Organic solute transporters alpha and beta (OSTα/β) form a heteromeric efflux structure
located in the basolateral membranes of human hepatocytes, kidney proximal tubule cells
and importantly, enterocytes (Ballatori et al., 2005). The primary endogenous substrates
of OSTα/β are bile acids, which require this transporter for efficient enterohepatic
recirculation (Seward et al., 2003). Following cellular influx, typically accomplished by
apically expressed uptake transporters such as ASBT, OSTα/β mediates absorption of
bile acids by moving intracellular compounds across the basolateral membrane of
enterocytes (Seward et al., 2003). OSTα/β is a bidirectional transporter that facilitates
movement of its substrates down their concentration gradients (Ballatori et al., 2005).
Due to their important role in intestinal bile acid reabsorption, it remains conceivable that
OSTα/β is involved in fexofenadine absorption. Therefore, if fexofenadine is a substrate,
the effect of fruit juices on OSTα/β function should be investigated.
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1.8.2.1

Mouse Orthologs of OSTα/β

The mouse orthologs of OSTα and OSTβ (mOstα and mOstβ) are located in the
basolateral membrane of mouse small bowel epithelia (Ballatori et al., 2005). Again,
fexofenadine transport and fruit juice effect on mOstα/β have never been examined.

1.8.3

Other Basolateral Efflux Transporters

MRP3 is another efflux transporter expressed in the basolateral membrane of gut
epithelial cells. The mRNA transcripts of this carrier molecule and its mouse ortholog,
mMrp3, are readily detected along the small intestine (Taipalensuu et al., 2001; Rost et
al., 2002). Fexofenadine is a substrate of both MRP3 and mMrp3, as determined by in
vitro and in vivo studies, respectively (Matsushima et al., 2008; Ming et al., 2011).
Currently, the effect of fruit juices on MRP3 and mMrp3 activities is not known.

1.9

Grapefruit Juice and Apple Juice Components That
May Be Responsible for FJDIs

In the original report by Dresser and colleagues (2002), AJ co-administration produced a
slightly greater reduction in fexofenadine plasma concentration than GFJ. Similarly for
the minimally-metabolized renin inhibitor drug, aliskiren, AJ co-ingestion led to a more
significant drop in oral bioavailability than with GFJ (Tapaninen et al., 2010; Tapaninen
et al., 2011). Differences in the magnitudes of effect among fruit juices on drug
absorption may relate to the concentrations of juice components and their interactions
with gut drug transporters. Flavonoids are plant secondary metabolites that have been
identified as the probable fruit juice constituents responsible for pharmacokinetic drug
interactions that involve non-metabolized medications (Bailey et al., 2007; Shirasaka et
al., 2013a). These phytochemicals provide pigmentation, protect against ultraviolet
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damage, participate in growth regulation and act as chemical defenses against plant
pathogens (Yao et al., 2004; Petrussa et al., 2013). As components of our diet, flavonoids
are considered natural antioxidants with protective roles in cancer, cardiovascular
disease, metabolic disorders and allergies (Yao et al., 2004).
With over 5000 identified flavonoids, the polyphenolic compounds are characterized by
their 15 carbon backbone (C6-C3-C6) (Yao et al., 2004) (Figure 1.4). They can be further
subdivided into the pertinent classes flavanone, flavonol and dihydrochalcone.
Naringenin and its glycosylated forms naringin (naringenin 7-O-neohesperidoside) and
narirutin (naringenin 7-O-rutinoside) and hesperitin and its glycosylated forms hesperidin
(hesperetin 7-O-rutinoside) and neohesperidin (hesperetin 7-O-neohesperidoside) are
common flavanones found in citrus fruits (Ross et al., 2000; Yao et al., 2004). The
flavonols quercetin and kaempferol and the dihydrochalcones phloretin and its
glycosylated form phloridzin (phloretin-2'-O-glucoside) are found in onions, broccoli and
apples (Yao et al., 2004; Shao et al., 2008).
Concentrations of flavonoids are variable between different fruit juices and brands. For
example, naringin, narirutin and hesperidin are highly concentrated in GFJ but not AJ,
while phloridzin, hesperitin and quercetin are readily detected in AJ but not GFJ (Ross et
al., 2000; Shirasaka et al., 2013a). Between juice brands, flavonoid concentrations are
affected by the source of the fruit and the techniques used to process and prepare the juice
(Yao et al., 2004). The predominant flavonoids are found at micromolar to millimolar
concentrations in fruit juices (Zhang, 2007).
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There have been two fexofenadine pharmacokinetic studies in humans involving coadministered flavonoids. In one study, relevant doses of naringin caused a reduction in
fexofenadine oral absorption with a magnitude of effect about half that found for GFJ
(Bailey et al., 2007). This finding suggests an important role for naringin in the
fexofenadine-GFJ interaction. In the other study, when subjects were co-treated with
quercetin (500 mg), surprisingly they experienced greater plasma fexofenadine
concentrations suggesting that this flavonol does not play a decisive role in the
fexofenadine-AJ interaction (Kim et al., 2009).
In vitro, GFJ, AJ and the specific flavonoids naringin and hesperidin have inhibitory
effects on OATP1A2 activity (Dresser et al., 2002; Bailey et al., 2007). In OATP2B1expressing cells in culture, transport activity was inhibited by AJ and GFJ (Shirasaka et
al., 2013b). Additionally, the flavonoids naringin, naringenin, hesperidin, hesperetin,
phloridzin, phloretin, quercetin and kaempferol all demonstrated inhibitory effects on in
vitro OATP2B1 transport activity (Shirasaka et al., 2013a). For OCT1 mediated
transport, AJ flavonoids quercetin and phloridzin but not the GFJ flavonoid naringin
attenuated activity in vitro (Mandery et al., 2012; Mimura et al., 2015). Overall, variable
flavonoid profiles may explain the in vitro discrepancies between AJ- and GFJ-drug
interactions and suggest that their affects on the oral absorption of drugs may differ.
It should be noted that furanocoumarins, a class of phytochemicals found distinctly in
GFJ, are thought to be responsible for drug metabolizing enzyme-mediated FJDIs (Guo
and Yamazoe, 2004). However, major furanocoumarins bergamottin and its metabolite
DHB do not elicit inhibitory effects on OATP mediated transport in vitro (Bailey et al.,
2007; Shirasaka et al., 2013a).
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Figure 1.4 Common flavonoids found in grapefruit juice and apple juice.
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1.10

Preclinical Fruit Juice-Fexofenadine Studies

Animal models may provide additional insights to elucidate the in vivo mechanisms of
FJDIs. Fexofenadine pharmacokinetics have been reported in rodent, porcine and primate
models (Cvetkovic et al., 1999; Tahara et al., 2005; Petri et al., 2006; Ogasawara et al.,
2007; van de Steeg et al., 2010). In rats and monkeys, co-administration with P-gp
inhibitors including cyclosporine A and ketoconazole, increased the bioavailability of
oral fexofenadine, a result consistent with human studies (Ogasawara et al., 2007; Ujie et
al., 2008). In P-gp KO mice (Mdr1a-/- and Mdr1a/b-/-), there was 4-5 times greater
fexofenadine plasma levels than WT mice after oral administration (Cvetkovic et al.,
1999; Tahara et al., 2005). In WT mice, oral fexofenadine bioavailability is only 2.38%
and much less than that measured in humans (33%) (Tahara et al., 2005; Smith and
Gums, 2009). These findings suggest that the expression and activity of mouse orthologs
of P-gp play more substantial roles in limiting intestinal fexofenadine absorption than
human P-gp. As mentioned previously, there are 4 mouse orthologs of human OATP1A2,
namely mOatp1a1, mOatp1a4, mOatp1a5 and mOatp1a6 (van de Steeg et al. 2010).
Another difference exists for liver-specific human OATP1B1 and OATP1B3 transporters
which have a single mouse ortholog, mOatp1b2. These species differences have
prompted the development of an Oatp1a/1b cluster KO mouse model which is deficient
in all mOatp1a transporters as well as mOatp1b2. Interestingly, intestinal fexofenadine
absorption in the Oatp1a/1b cluster KO mice was not significantly different than WT
mice (van de Steeg et al., 2010). This result, suggests minimal roles are played by
intestinal mouse Oatp1a transporters in oral fexofenadine absorption.
Interestingly, there is only a single reported study investigating the fruit juice-
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fexofenadine pharmacokinetic interaction in preclinical species. In 2005, Kamath and
colleagues showed in Sprague-Dawley rats that fexofenadine co-ingestion with AJ (28
mL/kg) resulted in a 28% reduction in oral drug exposure. While the direction of effect
on fexofenadine bioavailability in rats was consistent with that seen in humans, there was
a greater drop in AUC (78% reduction) with comparably less AJ volume (approximately
17mL/kg) in the clinical study (Dresser et al., 2002). Nevertheless, this finding suggests
that the rat model can recapitulate the human fruit juice-fexofenadine interaction.
The mouse may be a convenient preclinical model to further study the mechanisms of
FJDIs. Surprisingly, this model has never been reported previously as a tool to establish
the intestinal drug transporters involved. In this regard, it would be interesting to test
whether fruit juice-fexofenadine interactions occur in WT mice and compare effects to
mice with genetic deficiencies in intestinal fexofenadine transport proteins. Given that
intestinal Mdr1a acts more significantly in mice than humans to limit oral drug
absorption, a fruit juice-fexofenadine study in Mdr1a-/- mice may unmask the roles of
intestinal uptake transporters in the food-drug effect by eliminating dominant efflux
mechanisms. Studies in the Oatp1a/1b cluster KO mouse model have already indicated a
limited role for intestinal mOatp1a transporters in the bioavailability of fexofenadine. It
is possible that another intestinal mouse Oatp, namely, mOatp2b1, contributes to
fexofenadine absorption. Our laboratory has recently developed a novel mOatp2b1 KO
(Oatp2b1-/-) mouse model. With this mouse model, it may be possible to convincingly
demonstrate or rule out an in vivo role for mOatp2b1 in fruit juice-fexofenadine
interactions.
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2

2 Hypothesis and Specific Aims
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2.1

Statement of the Problem and Overall Hypothesis

Canada’s Food Guide endorses the consumption of fruit juice as a means to help meet the
daily-recommended intake of fruits and vegetables (http://www.hc-sc.gc.ca). Indeed, fruit
juices have become a common component of diet. However, in recent years, there has
been a growing appreciation that fruit juices interact with drugs in a manner that raises
serious concerns for patient safety. Particularly troublesome are fruit juice interactions
involving medications metabolized by CYP3A4, that result in marked elevations in
plasma drug concentrations and increased risk of drug toxicity. Less appreciated is the
fact that non-metabolized medications also interact with fruit juices, but in these cases the
outcome is a reduction in plasma drug concentrations and potential loss of efficacy. The
mechanisms underlying fruit juice interactions with non-metabolized drugs remain poorly
understood. In recent years, attention has been directed towards roles of intestinal drug
transporters in this food-drug effect. In this regard, OATP1A2 and OATP2B1, have
become the primary suspect mediators of FJDIs, despite that in vitro studies are not
entirely consistent with the clinical effect. This raises the possibility that there exist other,
yet to be discovered transporters involved. Moreover, essentially all support for specific
mechanisms of clinical fruit juice interactions with non-metabolized drugs have been
obtained from in vitro studies. Convincing in vivo studies that support proposed
mechanisms are currently lacking.
The overall hypothesis is that GFJ and AJ limit the absorption of fexofenadine
through their interactions with specific intestinal transporters.
As numerous oral medications on the market today rely on intestinal transport proteins
for absorption, individuals taking substrate drugs, which include commonly prescribed
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cardiovascular medications, may inadvertently be at risk for reduced drug efficacy due to
FJDIs. Understanding the molecular mechanisms behind fruit juice-non-metabolized drug
interactions will provide a basis for implementation of safer and more effective
pharmacotherapy, reducing the incidence of preventable ADEs and improving therapeutic
outcomes. Furthermore, potential fruit juice-drug interactions can be specifically
investigated for drugs in development prior to market release, allowing for more rational
drug design that minimizes the incidence of suboptimal therapy.

2.2

Specific Aim 1

To determine candidate intestinal transporters and their mouse orthologs
involved in the fruit juice-fexofenadine interaction.
While OATP1A2 and OATP2B1 have been proposed as key players of this food-drug
effect, the entire spectrum of intestinal transporters involved has not been fully
elucidated. Furthermore, current studies have largely focused on apically expressed
membrane proteins and have failed to consider the involvement of transporters located on
basolateral membrane of intestinal epithelial cells. Due to its physiochemical properties
and minimal breakdown by metabolic enzymes, fexofenadine serves as a prototypical
probe drug for transporter function. As such, the antihistamine was used throughout this
thesis for the study of enzyme independent-FJDIs. Additionally, GFJ and AJ have been
demonstrated to elicit both similar and differing in vivo effects on oral drug
bioavailability and in vitro modulation of drug transporter function, possibly due to their
distinct flavonoid compositions. Therefore, we sought to identify human intestinal
transporters involved in the GFJ and AJ-fexofenadine interaction. Moreover, we aimed to
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characterize the transport function of their murine orthologs as a prelude to in vivo
pharmacokinetic studies in mice.
We hypothesize that in addition to the previously suspected transporters, OATP1A2
and OATP2B1, other intestinal transport proteins involved in the fruit juicefexofenadine interaction exist.
To test this hypothesis, we performed an in vitro screen of a panel of intestinal
transporters and their murine orthologs for fexofenadine transport using a cellular
expression system. The flavonoid profiles of GFJ and AJ were measured and the effect of
each fruit juice on identified human and mouse fexofenadine transport proteins were
subsequently evaluated by in vitro fexofenadine transport inhibition studies. We expected
to find novel fexofenadine transporters that may be involved in the FJDI and that GFJ
and AJ would elicit fruit juice-specific effects on transporter activity.

2.3

Specific Aim 2

To establish whether the mouse can serve as an in vivo model for the fruit juicefexofenadine interaction and to investigate the role of mOatp2b1 in this fooddrug effect in vivo.
While clinical studies have localized the FJDI to the site of absorption and in vitro studies
have implicated several intestinal transporters in the effect, there remains some
disconnect between current findings and a paucity of supportive evidence from
preclinical models. Interestingly, there have been no reports to date which have evaluated
mice as a preclinical model for FJDIs. Moreover, while many drug transporter knockout
mouse models exist, surprisingly they have not yet been used to gain a better
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understanding of the in vivo roles of proposed transport proteins involved in FJDIs.
Therefore, we aimed to first characterize the mouse as an in vivo model of FJDIs. With
the recent development of a novel Oatp2b1-/- mouse model, the in vivo role of mOatp2b1
in FJDIs was evaluated.
We hypothesize that mice will faithfully recapitulate the human fruit juicefexofenadine interaction. Furthermore, the FJDI will be mediated through
inhibition of mOatp2b1 by GFJ in vivo.
To test this hypothesis, we conducted fruit juice-fexofenadine pharmacokinetic
interaction studies in WT and Oatp2b1-/- mice. We expected that fruit juice coadministration would result in a reduction in fexofenadine oral bioavailability in WT
mice. It was also expected that the plasma levels of fexofenadine would be lower in
Oatp2b1-/- mice in comparison to WT mice. We also reasoned that a reduction in
systemic fexofenadine levels would occur in WT but not in KO mice with fruit juice coingestion.
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3 Materials and Methods
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3.1

Materials

[3H]-Fexofenadine (78Ci/mmol, 99.7% radiochemical purity) was custom synthesized by
Quotient Bioresearch (Fordham, Cambridgeshire, UK) by non-specific labeling.
Unlabeled fexofenadine, fexofenadine-d6 and phloridzin were purchased from Toronto
Research Chemicals (Toronto, ON). Concentrated (4x) GFJ (Minute Maid, 100%
Grapefruit Juice Frozen Concentrate) and concentrated (4x) AJ (No Name, Apple Juice,
Frozen Concentrate) were acquired from Walmart (London, ON). The same GFJ and AJ
stocks were used for all fruit juice experiments. All other chemicals, unless otherwise
stated, were obtained from Sigma-Aldrich (St. Louis, MO).

3.2

Transporter Expression Plasmids

OATP1A2, OATP2B1, OCT1, OCT2, OCT3, ASBT, PEPT1, HCP1, P-gp and BCRP
expression plasmids were generated as previously described (Cvetkovic et al., 1999; Kim
et al., 2001; Tirona et al., 2003; Ho et al., 2006; Urquhart et al., 2008; Urquhart et al.,
2010; Posada et al., 2015). Constructs for OCTN1, OCTN2, MRP2, OSTα, OSTβ,
mOatp1a1, mOatp1a4, mOatp1a6, mOatp2b1, mOct3, mOstα and mOstβ were developed
in the Personalized Medicine Lab, London Health Sciences Centre – University Hospital
(unpublished data). mOct1 complementary deoxyribonucleic acid (cDNA) was amplified
from a mouse small intestine cDNA library (BioChain Institute, Inc.; Newark, CA) using
primers 5'-GGGCGCACCATGCCCACGTTCGACCAGGCA-3' (forward) and 5'ACAGGGGCCTCAGACATCAGAAGTAGAAAC-3' (reverse) by polymerase chain
reaction (PCR) with Expand Long Template Polymerase Chain Reaction System (Roche
Applied Science; Indianapolis, IN). The resulting amplicon was cloned into
pcDNA3.1/V5-His-TOPO expression plasmid (Invitrogen; Burlington, ON).
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3.3

Cell Culture

Human cervical adenocarcinoma (HeLa) cells were purchased from American Type
Culture Collection (Manassas, VA). Cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) (Thermo Fisher Scientific; Grand Island, NY) supplemented with 10%
fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM Lglutamine (Invitrogen), at 37°C, 5% CO2.

3.4
3.4.1

Transport and Inhibition Studies
Transient Transfection

HeLa cells were grown on 12-well plates (seeding density of 2.5 x 105 cells/well) at
37°C, 5% CO2. After 48 hours, cells were transfected by blank expression plasmids
(control) (Invitrogen) or expression plasmids containing transporter cDNA inserts using
Lipofectamine 3000 (Invitrogen) according to manufacturer’s instructions. In brief,
plasmid expression vectors were incubated with Lipofectamine 3000 and P3000 reagents
in Opti-MEM, a reduced serum media (Invitrogen), for 15 minutes (min) at room
temperature (RT). The DNA-lipid mixture (1 µg DNA/well) was then added to the
culture medium. Cells were incubated for 16 hours at 37°C, 5% CO2 prior to transport
experiments.

3.4.2

Transport Study

Transport studies were conducted to identify human and mouse fexofenadine transporters
according to methods described previously (Cvetkovic et al., 1999). [3H]-Fexofenadine
and the unlabeled drug (0.1 µM) were dissolved in phosphate buffered saline (PBS)
(Roche Applied Science) when evaluating OATP2B1 and mOatp2b1 transport or Krebs-
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Henseleit buffer (KHB) (1.2 mM MgSO4•7H2O, 0.96 mM KH2PO4, 4.83 mM KCl, 118
mM NaCl, 1.53 mM CaCl2•2H2O, 23.8 mM NaHCO3, 12.5 mM 4-[2-hydroxyethyl]-1piperazineethanesulfonic acid [HEPES], 5 mM glucose in water) for all other transporters
at pH 6 with the exception of human and mouse OCT and OCTN transporters where pH
7.5 was used. The drug dose (400 µL) was applied to cultured cells for 30 min at 37°C,
5% CO2. Thereafter, cells were washed three times rapidly with ice-cold PBS. To
quantify cellular drug accumulation, cells were lysed using 1 mL of 1% sodium dodecyl
sulfate (SDS) in water (v/v) and intracellular radioactivity was measured by liquid
scintillation spectrometry (Tri-Carb 3900TR; Perkin Elmer; Waltham, MA). To evaluate
OATP2B1- and mOatp2b1- mediated fexofenadine uptake, unlabeled fexofenadine (100
µM) was dissolved in PBS at pH 6 and applied to culture cells for 30 min. Cells were
subsequently washed with ice-cold PBS and lysed using 400 µL of acetonitrile spiked
with internal standard (fexofenadine-d6, 10 ng/mL). Intracellular fexofenadine was
measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (described
in Section 3.5).

3.4.3

Inhibition Study

Inhibition studies were conducted to evaluate the in vitro effects of fruit juices on
transporter mediated fexofenadine uptake. Concentrated (4x) GFJ and AJ were diluted to
normal strength (1x) with KHB. [3H]-Fexofenadine and unlabeled fexofenadine (0.1 µM)
were dissolved in 5% normal strength GFJ or AJ in KHB (v/v) and exposed to cultured
cells for 30 min. Juice and control dose solutions were all adjusted to pH 6. Under these
conditions, 5% GFJ and 5% AJ are sufficient to elicit inhibitory effects on drug transport
while avoiding cytotoxicity (Dresser et al., 2002). After incubation with the drug dose,
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cells were washed, lysed and intracellular radioactivity was quantified by liquid
scintillation spectrometry. To examine the effect of GFJ on OATP2B1 and mOatp2b1
mediated fexofenadine transport, unlabeled fexofenadine (100 µM) was dissolved in 5%
GFJ in PBS (v/v) at pH 6 and incubated with the expression systems for 30 min. Cells
were washed, lysed and intracellular fexofenadine was quantified by LC-MS/MS.

3.5
3.5.1

Fexofenadine LC-MS/MS Quantification
Sample Preparation

Cell lysates (in acetonitrile spiked with internal standard) from transport and inhibition
studies were centrifuged for 10 min at 13,500 rpm in a microcentrifuge. An aliquot of the
resulting supernatant (40 µL) was diluted with 160 µL of 0.1% formic acid in water (v/v).
Standard curve samples were created by adding increasing concentrations of
fexofenadine diluted in water which were subsequently processed in a similar fashion as
cell lysate samples.
Plasma samples (5 µL) were spiked with internal standard (fexofenadine-d6, 5 µL, 200
ng/mL), precipitated with acetonitrile (15 µL) and centrifuged for 10 min at 13,500 rpm.
The resulting supernatant (20 µL) was diluted with 125 µL of 0.1% formic acid in water
(v/v). Standard curve samples were created by spiking fexofenadine into blank human
ethylenediaminetetraacetic acid

EDTA) plasma (Bioreclamation IVT; Baltimore, MD)

for subsequent processing similar to plasma samples.

3.5.2

LC-MS/MS Conditions

Analytes were separated by liquid chromatography (Agilent 1200; Agilent; San Clara,
CA) using Hypersil Gold reversed-phase column (50 × 3 mm, 5 µm particle size; Thermo

46

Fisher Scientific) following sample injection (50 µL for cell lysate samples and 75 µL for
plasma samples). A mobile phase of 0.1% v/v formic acid in water (A) and acetonitrile
(B) was used, with an elution gradient of 20% B from 0-1 min, 20-95% B from 1.0-4.5
min, 95% B from 4.50-5.25 min, 95-20% B from 5.25-5.80 min and 20% B from 5.8-6.0
min, for a run time of 6 min and flow rate of 0.5 mL/min. The heated electrospray
ionization source of the triple quadrupole mass spectrometer (Thermo TSQ Vantage;
Thermo Fisher Scientific) was operated in positive mode (3500 V, 350oC) with collision
energy set at 25 V. Additional ionization source conditions used were as follows: 40
arbitrary units for sheath gas pressure, 15 arbitrary units for auxiliary gas pressure and
350°C for capillary temperature. Selected reaction monitoring for fexofenadine and
fexofenadine-d6 was performed using mass transitions 502.2 → 466.5 m/z and 508.2 →
472.5 m/z, respectively. Both solutes had chromatographic retention time of 3.2 min.
Standard curves were linear over the concentration ranges of 2.5-100 ng/mL for cell
lysates and 2-100 ng/mL for plasma samples.

3.6
3.6.1

Flavonoid LC-MS/MS Quantification
Sample Preparation

Concentrated (4x) GFJ and AJ (100 µL) and plasma samples (50 µL) were precipitated
1:3 (v/v) with 50% acetonitrile in methanol (v/v) and centrifuged for 10 min at 13,500
rpm. The resulting supernatant (100 µL from fruit juices and 50 µL from plasma) was
diluted 1:2 (v/v) in 0.1% formic acid in water (v/v). Flavonoid standard curves were
created for juice and plasma in 0.1% formic acid in water (v/v) and blank control plasma
(Bioreclamation IVT), respectively.
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3.6.2

LC-MS/MS Conditions

Naringin, narirutin, hesperidin, neohesperidin, phloretin, quercetin and kaempferol
concentrations were analyzed by ultra-high pressure liquid chromatography-tandem mass
spectrometry (UHPLC-MS/MS), consisting of an Agilent 1290 liquid chromatography
system (Agilent) and Thermo TSQ Quantum Ultra triple quadrupole mass spectrometer
(Thermo Fisher Scientific). Analytes were separated on a Kinetex reversed-phase column
(50 × 3 mm, 5 µm particle size; Phenomenex, Torrence, CA) following sample injection
(5 µL). A mobile phase of 0.1% v/v formic acid in water (A) and 50% v/v acetonitrile in
methanol (B) was used, with an elution gradient of 25% B from 0.0-1.5 min, 25-95% B
from 1.5-7.0 min, 95-25% B from 7-9 min and 25% B from 9.0-9.5 min, for a run time of
9.5 min and flow rate of 0.5 mL/min. Mass spectrometer ionization conditions used were
as follows: 15 arbitrary units for sheath gas pressure, 5 arbitrary units for auxiliary gas
pressure and 300°C for capillary temperature. Naringin, narirutin, hesperidin,
neohesperidin, phloretin, quercetin and kaempferol were subjected to collision energies
of 17, 17, 19, 19, 17, 28 and 31 V, respectively for detection in positive mode using mass
transitions 581.2 → 273.0 m/z, 581.2 → 273.0 m/z, 611.2 → 303.0 m/z, 611.2 → 303.0
m/z, 275.1 → 107.1 m/z, 303.1 → 229.1 m/z and 287.1 → 153.1 m/z, respectively with
solute retention times of 1.95, 1.65, 2.10, 2.42, 2.61, 2.42 and 3.31 min, respectively.
Naringenin, hesperetin and phloridzin concentrations were analyzed separately by LCMS/MS instrumentation and source conditions as described in Section 3.5.2. A mobile
phase of 0.1% v/v formic acid in water (A) and 50% v/v acetonitrile in methanol (B) was
used, with an elution gradient of 25% B from 0.0-1.5 min, 25-95% B from 1.5-6.0 min,
95% B from 6.0-7.0 min, 95-25% B from 7.0-8.0 min and 25% B from 8.0-8.5 min, for a
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run time of 8.5 min and flow rate of 0.5 mL/min. Naringenin, hesperetin and phloridzin
were subjected to collision energies of 21, 27 and 18 V and detected in negative mode
using mass transitions 272.2 → 151.0 m/z, 301.1 → 164.1 m/z and 435.2 → 273.2 m/z
with chromatographic retention times of 4.40, 4.53 and 3.64 min, respectively
Standard curves for flavonoids in juice were linear over the ranges of 60-300, 40-200, 1050, 20-100, 0.02-0.10, 0.6-3.0, 0.02-0.10, 0.01-0.1, 0.2-1.0 and 2-10 µg/mL for naringin,
narirutin, hesperidin, neohesperidin, phloretin, quercetin, kaempferol, naringenin,
hesperetin and phloridzin, respectively. The lower limits of quantification in plasma were
6, 4, 1, 2, 0.006, 0.06, 0.006, 0.004, 0.02 and 0.2 µg/mL for naringin, narirutin,
hesperidin, neohesperidin, phloretin, quercetin, kaempferol, naringenin, hesperetin and
phloridzin, respectively.

3.7

Animals

Adult, male mice were used in all experiments to limit age- and sex-dependent variation
in intestinal drug transporter expression (Cheng et al., 2005). Oatp2b1-/- mice
(Slco2b1tm1a(KOMP)Wtsi) were generated in collaboration with the Knockout Mouse Project
at UC Davis (manuscript in preparation). In this mouse model, a gene trap cassette was
inserted into the Slco2b1 gene in Intron 3 of C57BL/6J mice by homologous
recombination in embryonic stem cells to produce global knockdown of Oatp2b1 gene
expression. Preliminary investigations indicate that Oatp2b1-/- mice are viable, fertile and
produce litters of normal size. Serum biochemistry and histological analysis of Oatp2b1/-

mice are unremarkable. C57BL/6 mice (WT background strain of Oatp2b1-/- mice) were

obtained from Jackson Laboratories (Bar Harbor, MA). Mdr1a-/- mice (Crl/CF1-
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Abcb1amds) and its corresponding WT strain, CF-1 mice, were purchased from Charles
River Laboratories, Inc. (Wilmington, MA). C57BL/6 and Oatp2b1-/- mice were
maintained in a barrier, sterilized, temperature controlled, animal facility, following a 12hour light/dark cycle. CF-1 and Mdr1a-/- mice were housed in a conventional,
temperature controlled, animal facility, following a 12-hour light/dark cycle. Standard
chow diet and water were available to all mice ad libitum.

3.8

Mouse Pharmacokinetic Study

To determine the in vivo effect of fruit juices on fexofenadine exposure, pharmacokinetic
studies were conducted in adult, 10-19 week old C57BL/6, Oatp2b1-/-, CF-1 and Mdr1a-/mice. Animals were fasted for 4 hours prior to drug administration. Mice were
administered fexofenadine (1 mg/kg) dissolved in 200 µL of PBS (pH equivalent to GFJ
and AJ), 4x concentrated GFJ or 4x concentrated AJ, by oral gavage. Blood (30 µL) was
sampled from the saphenous vein at 5, 15, 30 min and 1, 2 and 3 hours post drug
administration and stored in heparinized microcentrifuge tubes. Following the 1-hour
blood sampling, subcutaneous saline (1 mL) was administered as fluid replacement. Mice
were euthanized by isoflurane at the 3 hours and a final blood sample (500 µL) was
collected by cardiac puncture. Blood samples were centrifuged at 5000g for 10 min, 4oC.
Plasma (200 µL from final time point, 10 µL from all other time points) was obtained and
stored at -80oC until fexofenadine and flavonoid levels were measured by LC-MS/MS.
This animal study protocol (No. 2014-012) was approved by Western University’s
Animal Use Subcommittee (London, ON).
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3.9

Pharmacokinetic Analysis

Plasma fexofenadine concentration-time curves were generated. Area under the plasma
concentration-time curve from 0 to 3 hours (AUC0-3) was calculated by the linear
trapezoidal method. Peak plasma concentration (Cmax) and time to reach peak plasma
concentration (Tmax) were determined directly from the data obtained.

3.10

Mouse Intestinal Permeability Study

To explore the possibility of intestinal mucosa damage by GFJ, an intestinal permeability
test was performed in adult, 10 week old WT (CF-1) and Mdr1a-/- mice. Following a
protocol described by Johnson et al. (2015), mice were fasted for 6 hours then
administered fluorescein isothiocyanate labelled dextran (FITC-dextran, 4 kDa), at 600
mg/kg dissolved in either 200 µL of PBS or 4x concentrated GFJ by oral gavage. At 1hour post administration, 130 µL of blood was collected from the saphenous vein and
centrifuged at 12,000 g for 3 min. Plasma was collected and diluted 1:2 (v/v) in PBS.
FITC-dextran concentration in plasma, an indicator of paracellular absorption, was
measured by fluorescence spectroscopy (excitation at 485nm, emission at 535nm) on a
Luminoskan Ascent instrument (Thermo Fisher Scientific). FITC-dextran doses, blood
and plasma samples were protected from light exposure. Mice were returned to the
conventional animal facility for recovery following the experiment.

3.11

Statistics

Unpaired, two-tailed, Student’s t-test or one-way or two-way analysis of variance
(ANOVA) with Bonferroni’s multiple comparisons test were used to determine statistical
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differences between groups. Statistical significant was deemed at a P value of <0.05. All
statistical analysis was conducted using GraphPad Prism Version 6.0f (La Jolla, CA).

52

4

4 Results
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4.1

Fexofenadine is a Substrate of Multiple Intestinal
Transporters and their Mouse Orthologs

Clinical studies have suggested that fruit juices limit intestinal fexofenadine absorption, a
process mediated by enterocyte uptake and efflux transporters (Banfield et al., 2002;
Dresser et al., 2002; Glaeser et al., 2007). While the antihistamine is a well described in
vitro substrate of OATP1A2, OATP2B1 and P-gp, (Cvetkovic et al., 1999; Dresser et al.,
2002; Nozawa et al., 2004), the entire complement of intestinal transport proteins
involved in its absorption has not been fully elucidated. Additionally, there have been no
reports demonstrating transport by mouse orthologs of the human fexofenadine
transporters. Species differences in drug transporter substrate specificity may impact the
use of mouse as a relevant model to understand mechanisms of FJDIs. Therefore, we
conducted transport experiments using a HeLa cell expression system to identify
additional candidate in vivo human and mouse fexofenadine transporters.

4.1.1

Identification of Fexofenadine Uptake Transporters

We performed transient transfection of a variety of intestinal transporters in cultured
HeLa cells to screen for novel fexofenadine transporters. Transfection and functional
heterologous expression were validated for mOatp1a1, mOatp1a4, mOatp1a6, OATP2B1,
mOatp2b1 and mOct1 by demonstrating transport of known substrates and plasma
membrane localization by immunofluorescence microscopy (for mOatp2b1 only)
(Appendix A: Transfection Validation, Supplementary Figures 1 and 2). For uptake
membrane proteins, the degree of intracellular fexofenadine accumulation after 30 min
drug exposure was used as a measure of transport activity. Fexofenadine uptake was then
reported as a percent of uptake by blank vector control transfected cells. While additional
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replicates were required for statistical analysis (n = 2), fexofenadine uptake by cells
expressing OATP1A2 was 2.6-fold higher than control cells transfected with blank vector
control plasmid, in accordance with previous reports (Dresser et al., 2002). Likewise, the
mouse orthologs, mOatp1a1 and mOatp1a4 significantly transported fexofenadine, albeit
to a lesser efficiency than OATP1A2 (19% and 41% greater than control, respectively,
P<0.0001). However, mOatp1a6 exhibited negligible drug uptake, suggesting substrate
specificity differences between mouse Oatp1a transporters (Figure 4.1 A). Although
OATP2B1 has previously been described as a fexofenadine transport protein, in our in
vitro expression system, the antihistamine did not appear to be a substrate of the human
transporter as intracellular drug levels were comparable between OATP2B1 expressing
cells and control cells (Figure 4.1 B) (Nozawa et al., 2004; Imanaga et al., 2011;
Shirasaka et al., 2011; Shirasaka et al., 2013b; Akamine et al., 2014; Akamine, 2015). On
the other hand, uptake of the antihistamine by the mouse ortholog, mOatp2b1, was 22%
higher than control (P<0.0001) (Figure 4.1 B). Interestingly, fexofenadine was a
substrate of both OCT1 and mOct1, as they showed significantly greater cellular drug
accumulation when compared to their respective controls (19% and 76% higher than
control, P<0.001 and P<0.0001, respectively). Other human OCT and OCTN family of
transporters, as well as ASBT, PEPT1 and HCP1 did not appear to transport the
antihistamine. While these findings do not definitively rule out the contribution of these
transporters in mediating intestinal fexofenadine absorption, it suggests limited roles
played by these membrane proteins (Figure 4.1 C, D and E). Overall, the current
findings would suggest that if expressed in the intestinal apical membrane, fexofenadine
absorption may be mediated by OATP1A2 and OCT1 in humans and mOatp1a1,
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mOatp1a4, mOatp2b1 and mOct1 in mice.

Figure 4.1. Fexofenadine transport by HeLa cells expressing human intestinal uptake
transporters and their mouse orthologs. HeLa cells transiently transfected with human or
human and mouse orthologs of (A) OATP1A2, (B) OATP2B1, (C) OCTs, (D) OCTNs
and (E) other uptake transporters were evaluated for intracellular accumulation of [3H]fexofenadine (0.1 µM for A, C, D and E) or unlabeled fexofenadine (100 µM for B) at
pH 6 (A, B and E) or pH 7.5 (C and D) following a 30-minute incubation period. Data are
expressed as percent of vector control, mean ± SEM, n = 1 for OCTN1 OCTN2, OCT2,
ASBT, PEPT1 and HCP1, n = 2 for OATP1A2 and mOct3 and n ≥ 3 for controls and all
other transporters. Student’s t-test was conducted, where ***P<0.001 and ****P<0.0001
represent significant differences from vector control.
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Figure 4.1 Fexofenadine transport by HeLa cells expressing human intestinal
uptaketransporters and their mouse orthologs.

57

4.1.2

Identification of a Novel Fexofenadine Basolateral Efflux
Transporter

OSTα/β is a bidirectional transporter that facilitates substrate movement down their
chemical gradient and is implicated in basolateral bile acid efflux by enterocytes
(Ballatori et al., 2005). In vitro, exposing OSTα/β expressing cells to extracellular
fexofenadine prompts cellular uptake of the drug. Interestingly, intracellular fexofenadine
retention was 45% (P<0.0001) higher than vector control in OSTα/β transfected cells
(Figure 4.2). Analogous to its human ortholog, the antihistamine appeared to be a
substrate of mOstα/β. However, strong conclusions cannot be drawn from this result and
no statistical analysis was performed as mOstα/β transport experiments were conducted
on two occasions (n = 2) with technical replicates. Overall, it would appear that
fexofenadine is a convincing, novel in vitro substrate of OSTα/β and probable, novel in
vitro substrate of mOstα/β, suggesting that these transporters may play a role in the
intestinal absorption of fexofenadine.
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Figure 4.2 Fexofenadine transport by HeLa cells expressing human intestinal basolateral
efflux transporter and its mouse ortholog. HeLa cells transiently transfected with
basolaterally localized OSTα/β and mOstα/β were evaluated for intracellular
accumulation of [3H]-fexofenadine (0.1 µM) at pH 6 following a 30-minute incubation
period. Data are expressed as percent of vector control, mean ± SEM (n = 2 for mOstα/β
and n ≥ 4 for controls and OSTα/β). Student’s t-test was conducted, where ****P<0.0001
represent a significant difference from vector control.
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4.2

Flavonoid Profiles of GFJ and AJ

Flavonoids have been proposed as the fruit juice components responsible for causing
transporter dependent FJDIs. GFJ and AJ possess different flavonoid compositions that
may explain the greater reduction in oral drug bioavailability observed with AJ coadministration when compared to GFJ (Dresser et al., 2002; Tapaninen et al., 2010;
Tapaninen et al., 2011). Furthermore, individual flavonoids have been shown to elicit
unique in vivo effects on fexofenadine exposure and in vitro effects on transporter
activity (Bailey et al., 2007; Kim et al., 2009; Mandery et al., 2012; Shirasaka et al.,
2013b; Mimura et al., 2015). To ensure that the fruit juices used in our experiments
contained the expected chemical components and in consideration of fruit juice-specific
effects, the concentrations of major flavonoids in 4x concentrated GFJ and AJ were
measured by LC-MS/MS.
Similar to what has been reported in the literature, naringin, narirutin, neohesperidin and
hesperidin were the most concentrated flavonoids in GFJ while phloridzin was the
predominant flavonoid in AJ (Shirasaka et al., 2013a). These results highlight the fact
that the major flavonoid constituents differ between GFJ and AJ. As expected,
naringenin, the aglycone of both naringin and narirutin was not a significant component
in GFJ. Although quercetin was expected to be a major flavonoid in AJ, greater levels of
this fruit juice component was detected in GFJ (Yao et al., 2004; Shirasaka et al., 2013a;
Mimura et al., 2015). Furthermore, we expected prominent levels of hesperitin in AJ,
however, its glycosylated forms hesperidin and neohesperidin were found at significantly
greater concentrations (Shirasaka et al., 2013a). In general, flavonoid concentrations in
the 4x concentrated GFJ and AJ were higher than those reported in the literature for
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normal strength fruit juices (Table 4.1). Together, these findings indicated that the GFJ
and AJ used in our experiments contained the proposed flavonoid mediators of fruit juice
interactions at high concentrations. Furthermore, their unique flavonoid profiles may
explain differences in the in vitro and in vivo fruit juice specific effects on drug transport.
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Table 4.1 Flavonoid concentrations in 4x concentrated grapefruit juice (GFJ) and 4x
concentrated apple juice (AJ) used in experiments and literature reports.
Flavonoid
Naringin
Narirutin
Naringenin
Hesperidin
Neohesperidin
Hesperitin
Quercetin
Kaempferol
Phloridzin
Phloretin

GFJ
(n = 6)
2540 ± 80
874 ± 41
0.44 ± 0.03
99.0 ± 5.0
412 ± 18
0.28 ± 0.01
24.8 ± 1.4
5.80 ± 0.24
1.1 ± 0.2
Not detectable

Concentration (µM)
GFJ in
AJ
Literature
(n = 7)
140 - 1640
Not detectable
45 - 210
Not detectable
0 - 450
Not detectable
25 - 50
3.4 ± 0.2
5 - 20
2.0 ± 0.5
0.6
0.13 ± 0.03
0.005 - 30
0.2 ± 0.06
0.02
0.02 ± 0.003
0.005
106 ± 5.2
0.001
1.56 ± 0.05

AJ in
Literature
0 - 0.001
0
0.001
0 - 0.2
0
1.5
0.5-3
0-0.7
17-100
0.2

Data are presented as mean ± SEM. Literature values are presented for 1x concentrated GFJ and AJ and
obtained from Gliszczynska-Swiglo and Tyrakowska (2003), Mullen et al. (2007), Zhang (2007), GodyckiCwirko et al. (2010) and Shirasaka et al. (2013a).
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4.3

Effects of GFJ and AJ on Human and Mouse
Fexofenadine Transporters

Having identified candidate human intestinal fexofenadine transporters and their mouse
orthologs (Section 4.1), we next sought to determine the in vitro effects of GFJ and AJ on
their transport activities. HeLa cells, transiently expressing transporters were exposed to
fexofenadine dissolved in control medium, 5% normal strength GFJ or 5% normal
strength AJ and intracellular drug accumulation was measured 30 min after drug
administration. Fexofenadine uptake was reported as a percent of uptake relative to blank
vector control transfected cells, exposed to control medium.
There was strong fruit juice inhibition of fexofenadine uptake by OATP1A2 expressing
cells as intracellular drug levels was reduced by 63% (GFJ) and 54% (AJ) upon juice
exposure. This finding agreed with the report by Dresser et al. (2002). Similarly, GFJ and
AJ significantly inhibited mOatp1a1 mediated fexofenadine cellular accumulation by
18% (P<0.001) and 12% (P<0.05) respectively. For mOatp1a4, there was a juice specific
effect on fexofenadine transport evidenced by an effect of GFJ (28% reduction in drug
uptake, P<0.0001) but not AJ on cellular drug accumulation (Figure 4.3 A).
In experiments with OATP2B1, we found that GFJ decreased fexofenadine cellular
retention in both vector control and OATP2B1 expressing cells. Again, we did not
observe OATP2B1-specific transport of fexofenadine. Uptake difference (difference in
the intracellular accumulation of fexofenadine between cells exposed to control medium
and GFJ treatment within the same expression system) was not significantly different
between vector control and OATP2B1 transfected cells. Together, these findings suggest
that the effect of GFJ on the two expression systems is caused by GFJ inhibition of
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endogenous, HeLa cell, fexofenadine transporters and not a result of fruit juice inhibition
of transfected OATP2B1. In contrast to the human transporter, we found that transfection
of mOatp2b1 stimulated fexofenadine cellular accumulation. GFJ also reduced drug
uptake into mOatp2b1 expressing cells (P<0.0001). Interestingly, the uptake difference
calculated from the mOatp2b1 expression system was significantly greater than vector
control (P<0.05). These findings imply that in addition to endogenous transporters,
components of GFJ inhibit fexofenadine uptake by mOatp2b1 (Figure 4.3 B).
For organic cation transporters, it would appear that GFJ but not AJ attenuated influx of
the antihistamine mediated by OCT1 (18% reduction) and mOct1 (20% reduction)
(Figure 4.3 C). With OSTα/β, GFJ inhibited fexofenadine transport activity by 21%, but
interestingly AJ had no effect on OSTα/β-mediated drug accumulation (Figure 4.3 D).
Additional experimental replications are required to confirm these results. With mOstα/β,
neither fruit juice appeared to inhibit the transporter (Figure 4.3 D). However, this
experiment was performed once and therefore the (lack of) effect of fruit juices on
fexofenadine transport by mOstα/β requires further confirmation.
Taken together, these in vitro transporter inhibition results implicate the probable
involvement of OATP1A2, OCT1 and OSTα/β in the fruit juice-fexofenadine interaction
in humans. Furthermore, while GFJ appeared to inhibit all three transporters, AJ only
inhibited OATP1A2, demonstrating juice-type specific effects. With respect to mouse
transporters, the current in vitro data predicts that mOatp1a1, mOatp1a4, mOatp2b1 and
mOct1 could be potential players in a fruit juice-fexofenadine interaction if these proteins
are indeed expressed in the mouse enterocytes.

Figure 4.3. Fruit juice inhibition of fexofenadine transport by HeLa cells expressing
human intestinal fexofenadine transporters and their mouse orthologs. HeLa cells
transiently transfected with human and mouse orthologs of (A) OATP1A2, (B)
OATP2B1, (C) OCTs and (D) OSTα/β were evaluated for intracellular accumulation of
[3H]-fexofenadine (0.1 µM for A, C and D) or cold fexofenadine (100 µM for B) in
control medium, 5% grapefruit juice (GFJ) in vehicle or 5% apple juice (AJ) in vehicle,
at pH 6 (A, B and D) or pH 7.5 (C) following a 30-minute incubation period. Data are
expressed as percent of vector control cells exposed to control medium, mean ± SEM, n =
1 for GFJ and AJ treated OATP1A2 and mOstα/β, n = 2 for KHB treated mOstα/β, GFJ
and AJ treated OCT1, OSTα/β and mOct1 and n ≥ 3 for controls and all other
transporters/conditions. One-way ANOVA was conducted where *P<0.05, **P<0.01,
***P<0.001 and ****P<0.0001 represent significant differences from vehicle treated
cells within the same expression system.

300

Control Medium
5% GFJ
5% AJ

200

*** *

100

200
150

m
O
at
p1
a4

100
50

ct
O
m

Ve
ct
or

C
on
tro
l
Ve
ct
or

1

0

Control Medium
5% GFJ
5% AJ

100
50

β
α/
st
O
m

α/

Ve
ct
or

ST
O

Ve
ct
or

β

0

C
on
tro
l

[3H]-Fexofenadine Uptake
(% Vector Control)

D

m
O
at
p2
b1

B1
P2
AT
O

Ve
ct
or

C
on
tro
l

0

150

C
on
tro
l

50

Control Medium
5% GFJ
5% AJ

O
C
T1

**

m
O
at
p1
a1

C
on
tro
l

A2
****

**

200

C
on
tro
l

100

Ve
ct
or

P1
AT

C

Control Medium
5% GFJ

[3H]-Fexofenadine Uptake
(% Vector Control)

Fexofenadine Uptake
(% Vector Control)

150

O

Ve
ct
or

B

****

0

C
on
tro
l

A

[3H]-Fexofenadine Uptake
(% Vector Control)

64

Figure 4.3 Fruit juice inhibition of fexofenadine transport by HeLa cells expressing
human intestinal fexofenadine transporters and their mouse orthologs.
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4.4

Effect of GFJ Co-Administration on Fexofenadine
Pharmacokinetics in WT and Oatp2b1-/- Mice

In humans, fexofenadine co-ingestion with GFJ dramatically drops plasma drug exposure
(by up to 67%) with minimal changes to t1/2 and clearance (Dresser et al., 2002). Lately,
there has been much attention focused on intestinal OATP2B1 as the primary transporter
mediator of this food-drug effect. Unfortunately, we were unable to demonstrate
facilitation of fexofenadine uptake by this transporter in vitro. However, we had a unique
opportunity to study the in vivo role of mOatp2b1 with the recent development of a
transporter KO mouse in our laboratory. We have found mOatp2b1-mediated
fexofenadine transport, which was inhibited by fruit juices in vitro. Furthermore, mRNA
expression of the transporter in the mouse small intestine is well documented (Cheng et
al., 2005; Fu et al., 2016) (Appendix C: Expression of Fexofenadine Transporters in
Mouse Small Intestine, Supplementary Figure 4). Therefore, we investigated the in
vivo role of mOatp2b1 in the fruit juice-fexofenadine interaction using WT (C57BL/6)
and Oatp2b1-/- mice. A pharmacokinetic study was conducted whereby fexofenadine
(1mg/kg) was co-administered with 200 µL (volume equivalent to 500 mL or two glasses
of fluid ingestion in humans) of PBS (control) or 4x concentrated GFJ (used to magnify
the fruit juice effect) by oral gavage and plasma drug levels were measured at set
intervals post drug intake.
Fexofenadine was rapidly absorbed into circulation in both PBS treated WT and Oatp2b1/-

mice, with Tmax occurring within the first 15-30 min post drug administration, implying

early absorption of the drug across the proximal small bowel (Figure 4.4). Interestingly,
there was a lack of significant differences between Tmax, Cmax and AUC0-3 between WT
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and Oatp2b1-/- mice suggesting a limited role played by mOatp2b1 in fexofenadine
disposition (Table 4.2). Moreover, in contradiction to clinical findings, GFJ coadministration did not lead to a significant change in fexofenadine disposition in WT
mice as Tmax, Cmax, and AUC0-3 were not statistically different between PBS control and
GFJ groups (Table 4.2). However, there was a trend toward decreased fexofenadine
plasma concentrations at 15 min post drug administration in GFJ treated WT mice in
comparison to PBS control treated WT mice (P = 0.08) (Figure 4.4). In Oatp2b1-/- mice,
GFJ co-ingestion did not significantly alter fexofenadine pharmacokinetics (Table 4.2).
Taken together, these results indicate that mOatp2b1 does not play a significant role in
fexofenadine disposition nor is it responsible for GFJ interaction in the mouse in vivo.
Importantly, the WT (C57BL/6) mouse does not recapitulate the clinical GFJfexofenadine pharmacokinetic interaction, indicating that it is an inadequate model of the
human condition.

Fexofenadine Concentration (ng/mL)
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Figure 4.4 Role of mOatp2b1 in fexofenadine disposition following grapefruit juice
(GFJ) co-ingestion. Mean ± SEM plasma concentration-time curves of fexofenadine (1
mg/kg) after oral administration with 200 µL phosphate-buffered saline (PBS) or 4x
concentrated GFJ in wild-type (WT) (n = 7 for PBS and n = 5 for GFJ) and Oatp2b1-/- (n
= 4 for PBS and n = 4 for GFJ) mice.
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Table 4.2 Plasma pharmacokinetic parameters of fexofenadine (1 mg/kg) after oral
administration with 200 µL phosphate-buffered saline (PBS) or 4x
concentrated grapefruit juice (GFJ) in wild-type (WT) and Oatp2b1-/- mice.
Data are presented as mean ± SEM. AUC0-3 is area under the plasma drug concentration-time curve from

Parameters
AUC0-3 (ng h/mL)
Cmax (ng/mL)
Tmax (h)

WT (C57BL/6)
PBS (n = 7)
GFJ (n = 5)
22.4 ± 2.10
21.6 ± 3.52
18.0 ± 3.00
11.5 ± 1.00
0.37 ± 0.16
0.82 ± 0.18

Oatp2b1-/PBS (n = 4)
GFJ (n = 4)
24.1 ± 4.44
22.7 ± 3.22
18.4 ± 8.00
15.3 ± 3.03
0.23 ± 0.10
0.60 ± 0.47

0 to 3 hours. Cmax is peak plasma drug concentration. Tmax is time to reach peak plasma drug
concentration.
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4.5

Effects of GFJ and AJ Co-Administration on
Fexofenadine Pharmacokinetics in WT and Mdr1a-/mice

High Mdr1a efflux activity may be substantially more limiting to intestinal fexofenadine
absorption in mice than in humans (Cvetkovic et al., 1999; Tahara et al., 2005; Smith and
Gums 2009). This notion could explain the low oral fexofenadine bioavailability of less
than 3% in mice a value much lower than that found in humans (33%) (Cvetkovic et al.,
1999; Tahara et al., 2005; Smith and Gums, 2009). Indeed, in the Mdr1a-/- mouse model,
plasma fexofenadine levels have been previously reported to be 4-5 times higher than
WT mice (Cvetkovic et al., 1999; Tahara et al., 2005). We therefore hypothesized that in
normal WT mice, high Mdr1a efflux activity may mask the impact of inhibition of
fexofenadine uptake transport by fruit juices. We anticipated that by eliminating
significant efflux transport, the effects of fruit juice on oral fexofenadine bioavailability
may be exaggerated and thus more evident than that observed in WT mice. To that end,
we investigated the effect of GFJ and AJ on fexofenadine pharmacokinetics in WT and
Mdr1a-/- mice.
Mdr1a-/- mice exhibited a 2.75-fold increase in plasma fexofenadine exposure compared
to WT mice when the drug was administered in PBS control vehicle (P<0.01), a result
that is in agreement with previous reports (Cvetkovic et al., 1999) (Figure 4.5). This
finding confirms the dominant role of P-gp in determining fexofenadine bioavailability in
rodents. Concomitant ingestion of GFJ or AJ with fexofenadine did not significantly alter
the AUC0-3, Cmax or Tmax in WT (CF-1) mice. Similarly, no difference in any
pharmacokinetic parameter was observed in Mdr1a-/- mice following either juice intake
(Figure 4.5) (Table 4.3). Overall, it appears that while Mdr1a is a major determinant of
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fexofenadine bioavailability in vivo, the absence of its expression did not unmask a latent
fexofenadine-fruit juice interaction to recapitulate the human situation. Current mouse
models remain poorly reflective of the clinical fexofenadine-fruit juice interaction.

B

Fexofenadine Concentration (ng/mL)

A

Fexofenadine Concentration (ng/mL)
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Figure 4.5 Role of Mdr1a in fexofenadine disposition following fruit juice co-ingestion.
Mean ± SEM plasma concentration-time curves of fexofenadine (1 mg/kg) after oral
administration with 200 µL phosphate-buffered saline (PBS), (A) 4x concentrated
grapefruit juice (GFJ) or (B) 4x concentrated apple juice (AJ) in wild-type (WT) (n = 7
for PBS, n = 7 for GFJ and n = 8 for AJ) and Mdr1a-/- (n = 9 for PBS, n = 7 for GFJ and n
= 7 for AJ) mice.
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Table 4.3 Plasma pharmacokinetic parameters of fexofenadine (1 mg/kg) after oral administration with 200 µL phosphate-buffered
saline (PBS), 4x concentrated grapefruit juice (GFJ) or 4x concentrated apple juice (AJ) in wild-type (WT) and Mdr1a-/mice.
WT (CF-1)
Mdr1a-/Parameters
PBS (n = 7)
GFJ (n = 7)
AJ (n = 8)
PBS (n = 9)
GFJ (n = 7)
AJ (n = 7)
16.2 ± 3.51
14.5 ± 3.39
16.6 ± 2.44
43.6 ± 6.71**
52.2 ± 3.42
33.3 ± 6.84
AUC0-3 (ng h/mL)
Cmax (ng/mL)
12.4 ± 3.46
7.55 ± 1.84
9.68 ± 1.61
19.8 ± 2.78
23.7 ± 1.46
17.5 ± 3.16
Tmax (h)
0.66 ± 0.16
1.32 ± 0.26
1.08 ± 0.35
1.56 ± 0.33
1.72 ± 0.36
1.23 ± 0.37
Data are presented as mean ± SEM. AUC0-3 is area under the plasma drug concentration-time curve from 0 to 3 hours. Cmax is peak plasma drug concentration.
Tmax is time to reach peak plasma drug concentration.
**P<0.01 represents a significant difference from PBS treated WT mice.
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4.6

GFJ Does Not Compromise Intestinal Mucosa
Integrity

The lack of observable changes to fexofenadine plasma concentrations upon fruit juice
co-administration in mice, which differs from that observed in humans, may have
resulted due to a potential impact of fruit juices on intestinal mucosa integrity. Intestinal
epithelial cells form a protective barrier against the external environment through the use
of tight junctions (Assimakopoulos et al., 2011). It is considered that drugs such as
fexofenadine can only enter the systemic circulation through transcellular uptake via
solute carriers in the apical and basolateral enterocyte membranes (Han et al., 2013).
However, xenobiotics, dietary factors, enzymes and stress are factors that may disrupt
intestinal tight junctions (Assimakopoulos et al., 2011). Damaged mucosal integrity
increases intestinal permeability, leading to potential paracellular uptake of fexofenadine,
a process independent of transport proteins. As such, a reduction in plasma drug levels
due to inhibition of uptake transporters or induction of efflux transporters may be
overcome and masked by increased bioavailability due to paracellular absorption.
To explore the possibility that fruit juices caused intestinal mucosa damage, an intestinal
permeability test was performed in WT and Mdr1a-/- mice. Here, the cell-impermeable
compound, FITC-dextran, was orally administered to mice and differences in plasma
concentrations served as an indicator of altered intestinal paracellular transport. No
significant difference was observed in plasma FITC-dextran concentrations between PBS
control and GFJ treatments in WT mice (Figure 4.6). Likewise, GFJ did not significantly
affect FITC-dextran plasma levels in Mdr1a-/- mice. Furthermore, plasma FITC-dextran
concentrations were not significantly different between WT and Mdr1a-/- mice (Figure
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4.6). These results suggest that the administered GFJ does not alter intestinal tight
junctions. Furthermore, the plasma fexofenadine exposure differences that were observed
between WT and Mdr1a-/- mice were not related to differences in intestinal paracellular
permeability.
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Figure 4.6 Effect of grapefruit juice (GFJ) on intestinal permeability. Mean ± SEM
plasma concentration of FITC-dextran (600 mg/kg) after oral administration with 200 µL
phosphate-buffered saline (PBS) or 4x concentrated GFJ in wild-type (WT) (n = 4 for
PBS and n = 4 for GFJ) and Mdr1a-/- (n = 3 for PBS and n = 4 for GFJ) mice.
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4.7

Flavonoids are Minimally Absorbed in Mice

In humans, the site of the fruit juice-fexofenadine interaction has been localized to the
intestine, as fruit juices do not change fexofenadine t1/2 or clearance. This implies that
fruit juice flavonoids do not affect the activity of transport proteins in excretory organs
such as the kidney and liver. Furthermore, it suggests that fruit juice flavonoids do not
enter the circulation at appreciable levels to influence fexofenadine elimination pathways.
To determine if this is in fact the case, we attempted to measure the concentrations of
administered flavonoids after GFJ and AJ consumption in the mouse fexofenadine
pharmacokinetics studies at the final time point plasma sample (3 hours post juice
administration).
We were unable to detect any flavonoids (naringen, narirutin, naringenin, hesperidin,
neohesperidin, hersperitin, quercetin, kaempferol, phloridzin and phloretin) in mouse
plasma. Therefore, orally administered flavonoids are not likely present at sufficient
circulating concentrations to modulate the activity of transport proteins in the kidney and
liver. In mice, the fruit juice flavonoids would appear to impact fexofenadine
pharmacokinetics only in the gut.
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5

5 Discussion
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5.1

Summary of Main Findings

Although several intestinal drug transporters are proposed mediators of FJDIs involving
non-metabolized drugs such as fexofenadine, the exact transport proteins involved in vivo
and the mechanistic basis of the effect remains unclear. Our working hypothesis is that
GFJ and AJ limit the absorption of fexofenadine through their interactions with specific
intestinal transporters.
In Aim 1, we evaluated candidate gut transporters and their mouse orthologs involved in
the fruit juice-fexofenadine interaction. Here, we hypothesized that in addition to the
previously suspected transporters, OATP1A2 and OATP2B1, other intestinal transport
proteins involved in this food-drug effect exist. Using in vitro transporter screens, we
confirmed that OATP1A2 and OCT1 are intestinal fexofenadine transporters (Cvetkovic
et al., 1999; Dresser et al., 2002; Glaeser et al., 2007; Ming et al., 2011). However, we
did not find OATP2B1 to be a fexofenadine transporter, contrary to findings by other
investigators. Furthermore, we demonstrated that not only was OATP1A2 transport of
fexofenadine subject to fruit juice inhibition as previously reported, but also potentially
affected was OCT1, suggesting that this transporter may be a new player in FJDIs. One
of our most important findings was the identification of OSTα/β as a novel potential
contributor to the fruit juice-fexofenadine interaction as we showed for the first time that
it transports fexofenadine and is likely inhibited by GFJ in vitro. In support of studies
aimed to assess the mouse as a model for FJDIs, we have described for the first time that
mOatp1a1, mOatp1a4, mOatp2b1, mOct1 and mOstα/β, murine orthologs of human
intestinally expressed fexofenadine transporters, are also functional fexofenadine solute
carriers that are subject to fruit juice inhibition to varying degrees. Interestingly,
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mOatp2b1, mOct1, mOstα and mOstβ, but not mOatp1a1 and mOatp1a4 mRNAs are
expressed in the small bowel of mice (Cheng et al., 2005; Fu et al., 2016). Together,
these findings predicted that mOatp2b1 and mOct1 could contribute to fexofenadine
absorption in mice, while minimizing the potential roles for mOatp1a1 and mOatp1a4. In
vitro, GFJ inhibited all identified fexofenadine transporters, whereas AJ was only able to
elicit inhibitory effects on OATP1A2. This differential fruit juice effect may be explained
by the unique flavonoid composition of each juice that we characterized by LC-MS/MS.
Overall, these results support the hypothesis that in addition to the current suspected
OATPs, other intestinal transport proteins may be involved in this food-drug effect,
namely OCT1 and OSTα/β.
In Aim 2, we characterized the mouse as an in vivo model for the fruit juice-fexofenadine
interaction and investigated the in vivo role of mOatp2b1 in this food-drug effect. It was
hypothesized that mice would faithfully recapitulate the human fruit juice-fexofenadine
interaction. Furthermore, the FJDI would be mediated through inhibition of mOatp2b1 by
GFJ. However, we showed that mice do not recapitulate the human FJDI as GFJ coadministration resulted in no change to plasma fexofenadine exposure in WT mice.
Contradicting in vitro and gene expression findings obtained in Aim 1, studies in
knockout mice revealed that mOatp2b1 was not a significant contributor to fexofenadine
oral absorption and that this transporter was not involved in FJDIs in vivo. In an attempt
to unmask fruit juice effects on uptake transporters, we eliminated the significant
intestinal

efflux

activity

of

Mdr1a

by

conducting

fruit

juice-fexofenadine

pharmacokinetic experiments in Mdr1a-/- mice and its corresponding background strain
(CF-1) as control. Indeed, we found that Mdr1a is a substantial contributor to
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fexofenadine bioavailability and plasma levels in mice (Cvetkovic et al., 1999; Tahara et
al., 2005). However, its dominant activity in the gut did not mask the effect of fruit juices
on uptake fexofenadine transporters as GFJ and AJ co-ingestion did not alter
fexofenadine pharmacokinetics in Mdr1a-/- mice. Additionally, the lack of fruit juice
effect in mice was not due to changes in intestinal paracellular permeability resulting
from GFJ administration. Overall, the findings from the in vivo studies did not support
the hypothesis that the mouse is a good model for FJDIs.

5.2

The Intestine as the Site of FJDIs

The mechanisms of FJDIs involving non-metabolized drugs have been extensively
studied and debated over the last decade and a half. In the initial report in 2002, Dresser
and colleagues localized this food-drug effect to the site of intestinal drug absorption as
GFJ and AJ co-ingestion elicited no effects on fexofenadine t1/2 and renal clearance. Since
then, this idea that FJDIs is mediated through an intestinal mechanism has become
entrenched as subsequent clinical studies by Dresser et al., (2005), Bailey et al., (2007),
Glaeser et al., (2007), Won et al., (2013) and Akamine et al., (2014) have all observed
this lack of change in pharmacokinetic parameters describing of systemic drug
elimination with fruit juice co-intake. Evidence gathered from this thesis adds further
support for this notion. We found that in mice, flavonoids, the presumed transporter
inhibitors in fruit juices, were not detected in plasma post juice administration. This
suggests that these key constituents would not have the potential to act on transporters in
the liver and kidneys, organs of drug elimination, as they are not readily absorbed into
circulation to reach these distal sites at sufficient concentrations to affect fexofenadine
clearance. This finding is consistent with the fact that the major fruit juice flavonoids are
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glycosides that may be too hydrophilic to be absorbed by passive diffusion (Oteiza et al.,
2005). Therefore, interactions with transporter proteins likely occur prior to systemic
absorption, in the intestine. The aglycone-type flavonoids in fruit juices are thought to be
absorbed, but they are rapidly metabolized by glucuronidation during first-pass through
the intestine and liver (Lee and Reidenberg, 1998). Since we did not measure these
flavonoid metabolites in blood, it cannot be entirely ruled-out that some metabolized
components of fruit juices are present in circulation to alter drug elimination in liver and
kidney. However, it should be noted that should flavonoids or its metabolites be present
at sufficient concentrations systemically, their effects on transport proteins would have to
be stimulatory as opposed to their well accepted inhibitory effects, in order to cause a
decrease in plasma drug exposure.
While the current results have shed some new insights into the molecular basis of this
FJDI, no clear and compelling mechanisms have yet emerged. In fact, findings presented
by this thesis reduce support that OATP1A2 and OATP2B1 are the key transporters
involved. Furthermore, our results have provided support for additional players in the
fruit juice-fexofenadine interaction, namely OSTα/β and OCT1. Consequently, it
becomes more plausible that fruit juices interact with multiple fexofenadine uptake and
efflux transporters resulting in a complex pharmacokinetic interplay.
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5.3

5.3.1
5.3.1.1

Evidence to Support or Contradict a Role for
Specific Intestinal Transporters in Fruit JuiceFexofenadine Interactions
OATP1A2
Supportive Evidence

OATP1A2 was the first proposed mediator of the fruit juice-fexofenadine interaction.
Repeatedly, in vitro studies have shown that fexofenadine is an excellent substrate of the
drug transporter (Cvetkovic et al., 1999; Dresser et al., 2002; Bailey et al., 2007; Glaeser
et al., 2007; Won et al., 2013). Furthermore, influx of the antihistamine is inhibited by
GFJ, AJ and GFJ flavonoids naringin and hesperidin in cellular OATP1A2 expression
systems (Dresser et al., 2002; Bailey et al., 2007; Won et al., 2013). In support of its role
in FJDIs, our findings confirmed OATP1A2-mediated fexofenadine transport and fruit
juice inhibition in a HeLa cell model. As such, the OATP transporter is a candidate
mediator of FJDIs owing to strong in vitro support.

5.3.1.2

Contradictory Evidence

In spite of convincing in vitro evidence, the in vivo role of OATP1A2 remains highly
debated. Much of this is due to heterogeneity in reports regarding the mRNA and protein
expression of this membrane transporter in the small intestine. Recent studies using
highly sensitive and accurate methods such as targeted proteomics favor the absence of
OATP1A2 protein in human small bowel (Nishimura and Naito, 2005; Hilgendorf et al.,
2007; Meier et al., 2007; Eechoute et al., 2011; Drozdzik et al., 2014). To further
disqualify its involvement, a study found that intestinal fexofenadine oral absorption was
not altered in Oatp1a/1b KO mice when compared to WT mice, implying minimal roles
of mouse OATP1A2 orthologs in facilitating fexofenadine uptake from the gut (van de
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Steeg et al., 2010). Finally, while our findings demonstrate that mOatp1a1 and mOatp1a4
are fexofenadine transporters and are functionally inhibited by fruit juices in vitro, studies
have repeatedly shown that they are not expressed in the mouse small intestine (Cheng et
al., 2005; Fu et al., 2016). If these results for mouse transporters translate to humans, an
in vivo role of OATP1A2 in FJDIs would seem unlikely.

5.3.2
5.3.2.1

OATP2B1
Supportive Evidence

Recent literature reports have focused on OATP2B1 as the primary facilitator of FJDIs.
While we were unable to demonstrate fexofenadine uptake by OATP2B1 using a HeLa
cell expression system, similar to Glaeser et al. (2007), fexofenadine was found to be a
transport substrate of this OATP by other research groups using the Xenopus laevis
oocyte expression system (Nozawa et al., 2004; Imanaga et al., 2011; Shirasaka et al.,
2011; Shirasaka et al., 2013b; Akamine et al., 2014; Akamine, 2015). In other expression
systems, GFJ and AJ dramatically inhibited fexofenadine influx by the OATP2B1
transporter (Imanaga et al., 2011; Shirasaka et al., 2013b). There is also in vivo support
for the role of OATP2B1 in the fruit juice-fexofenadine interaction. First, OATP2B1 is
unquestionably expressed in the small intestine, where the food-drug effect is localized
(Kobayashi et al., 2003; Nishimura and Naito, 2005; Meier et al., 2007; Drozdzik et al.,
2014). Second, Imanaga et al. (2011) examined the AJ-fexofenadine interaction in a
cohort of individuals harboring the reduced function SLCO2B1 c.1457C>T genetic
polymorphism. They found that individuals with the variant allele experienced lower
fexofenadine exposure when the drug was taken alone and a less dramatic change to
fexofenadine AUC when the drug was taken with AJ in comparison to individuals
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carrying WT alleles. Taken together, it appears that fexofenadine is an in vivo substrate of
OATP2B1 and that the AJ-fexofenadine effect is mediated in part by the inhibitory
interaction of AJ with intestinal OATP2B1.

5.3.2.2

Contradictory Evidence

Despite persuasive in vitro and clinical support, our novel results reduce support for the
mechanistic involvement of OATP2B1 in the fruit juice-fexofenadine interaction. We
presented new findings that mOatp2b1 is an in vitro fexofenadine transporter and
experiences inhibition by GFJ. mOatp2b1 mRNA is detected at appreciable amounts in
the mouse small intestine (Cheng et al., 2005; Fu et al., 2016). Therefore, based on the in
vitro findings and expression reports, we presumed that a fruit juice-drug interaction in
the mouse model would be mediated by mOatp2b1 in vivo. Unexpectedly, fexofenadine
exposure in Oatp2b1-/- mice was not significantly different from WT mice. Furthermore,
GFJ co-intake did not alter fexofenadine pharmacokinetics in WT or Oatp2b1-/- mice.
Together, we demonstrated that despite in vitro transport and inhibition results and
reported expression data that all pointed towards the potential involvement of mOatp2b1
in vivo, this Oatp transporter does not play a significant role in neither fexofenadine
absorption nor the GFJ-fexofenadine interaction. The in vitro-in vivo disconnect revealed
by our results calls into question the presumed role of OATP2B1 in clinical FJDIs.

5.3.3
5.3.3.1

OCT1
Supportive Evidence

As OCT1 is localized to the apical membrane of intestinal epithelial cells, it has become a
contender in the FJDI mechanism (Han et al., 2013). Results from our experiments
confirmed that OCT1 mediates fexofenadine transport in vitro (Glaeser et al., 2007).
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Furthermore, we showed for the first time that transport of the antihistamine by the
membrane protein is likely inhibitable by GFJ in a cellular expression model. OCT1 has
also been implicated in the atenolol–AJ interaction. Mimura et al., (2015) found that the
beta-blocker was an OCT1 substrate and that transport could be inhibited by the AJ
flavonoids phloretin and quercetin. In our experiments, we did not observe AJ inhibition
of OCT1-mediated fexofenadine cellular uptake. This discrepancy can be attributed to the
5% normal strength AJ used in our experiments which translates to nanomolar
concentrations of phloretin and quercetin, rather than the micromolar levels used by
Mimura and colleagues. Therefore, there is some in vitro support for OCT1 as a
candidate mediator of FJDIs.

5.3.3.2

Contradictory Evidence

We found that mOct1 was an in vitro fexofenadine transporter that could be inhibited by
GFJ. Moreover, the solute carrier is localized to the apical membrane of mouse small
bowel epithelial cells (Han et al., 2013). Thus, it was reasonable to presume that there
could be a GFJ-fexofenadine interaction in mice that occurs at the level of intestinal
mOct1 (Han et al., 2013). However, no pharmacokinetic interaction was observed,
suggesting that mOct1 does not facilitate fexofenadine absorption in mice. These results
further highlight the many in vitro-in vivo disconnects that complicate our ability to
establish mechanisms.

5.3.4
5.3.4.1

OSTα/β
Supportive Evidence

We propose OSTα/β as a novel candidate transporter involved in fruit juice-fexofenadine
interactions because it transports fexofenadine and is inhibited by GFJ in vitro.
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Furthermore, its localization to the basolateral membrane of enterocytes implies that it
may promote the vectorial movement of fexofenadine for absorption across the
enterocyte in vivo and can potentially interact with inhibitory fruit juice components
(Ballatori et al., 2005).

5.3.4.2

Contradictory Evidence

Since OSTα/β is responsible for bile acid reabsorption in the gut, it follows that this
transporter could promote fexofenadine oral absorption (Ballatori et al., 2005). This
possibility is somewhat weakened by the fact that OSTα/β is expressed largely in the
ileum and therefore it would represent a pathway for the late-in-time absorption of
fexofenadine (Ballatori et al., 2005). However, oral fexofenadine is significantly
absorbed in the proximal (duodenum) and medial (jejunum) regions of the small intestine
(Smith and Gums, 2009). Importantly, plasma pharmacokinetic profiles indicate that the
fruit juice-fexofenadine interaction occurs shortly after co-administration, inconsistent
with mechanisms involving the distal small intestine. Moreover, because OSTα/β is
expressed on the basolateral ileocyte membrane, flavonoids require traversal of the brush
border membrane of enterocytes to have access to the transporter. However, most fruit
juice components have very poor membrane permeability that likely limits their ability to
interact as sufficient levels to inhibit OSTα/β (Oteiza et al., 2005). This poor passive
membrane permeability is evidenced by the lack of detectable flavonoids in the plasma of
mice administered fruit juices.

On the other hand, non-glycoside flavonoids are

membrane permeable and in fact, several gut transporters including OATP1A2,
OATP2B1 and OCT1 can drive the cellular uptake of quercetin (Glaeser et al., 2014).
These types of flavonoids are more likely to interact with OSTα/β.
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5.4
5.4.1

Future Studies
In Vivo Role for OCT1 and OSTα/β

Our findings have implicated the involvement of two new candidate transporters, OCT1
and OSTα/β, in the fruit juice-fexofenadine interaction. Although we have provided in
vitro support for their roles, much like current proposed mediators, their in vivo
contributions remain to be elucidated. Luckily, transporter KO mouse models exist for
mOct (Oct1-/-) and mOstα (Ostα-/-) which may be used to address this knowledge gap
(Jonker et al., 2001; Soroka et al., 2010). It is notable that because mOstα/β function as a
heteromeric complex, KO of mOstα results in the dramatic reduction of mOstβ protein
expression in the gastrointestinal track of mice, sufficiently eliminating mOstα/β function
(Rao et al., 2008). Future fexofenadine pharmacokinetic interaction studies with GFJ and
AJ should be performed in these transporter KO mice to determine their in vivo roles in
drug absorption and the FJDI. Additionally, it may be beneficial to generate dual
transporter KO mice, combining Mdr1a with a suspected transporter to minimize
dominant efflux activity.

5.4.2

Do Fruit Juices Stimulate Apical Efflux Transporter Activity in
the Gut?

One of the earliest proposed mechanisms for FJDIs involving intestinal transporters was
the possibility that GFJ could “activate” P-gp (Soldner et al., 1999). Such stimulation of
P-gp on the apical enterocyte membrane would result in reduction of oral bioavailability
of both metabolized and non-metabolized drugs. However, this notion has since been
dismissed as fruit juices and their associated flavonoids have mostly been found to inhibit
P-gp (Takanaga et al., 1998; de Castro et al., 2007; Shirasaka et al., 2010). Another more
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likely possibility is that fruit juices stimulate the activity of apically-expressed MRP2 in
the gastrointestinal tract. We found that fexofenadine is a likely transport substrate of
MRP2 (Appendix B: Identification of Fexofenadine Apical Efflux Transporters,
Supplementary Figure 3) and many compounds have been found to stimulate MRP2
activity in a species-specific manner (Lagas et al., 2009). Moreover, flavonoids and their
metabolites are well-known substrates of MRP2 (Morris and Zhang, 2006). Therefore
future studies should examine whether fruit juices and their individual constituents
stimulate the activity of apical fexofenadine efflux transporters in the gut such as MRP2.

5.4.3

Are Unknown Fexofenadine Transporters Involved?

We found that the clinical fruit juice-fexofenadine interaction could not be reproduced in
mice. While disappointing, such species differences may however provide some clues to
the FJDI mechanism. It is possible that the fruit juice-fexofenadine interaction may be
attributed to the existence of unknown transport proteins. For instance, humans may
possess a currently unrecognized fexofenadine transporter that is not found in mice
through which the FJDI is mediated. It is also plausible that there exists an unknown
fexofenadine transporter found in both humans and mice that is subject to human-specific
inhibition by fruit juices. In light of the fact that we already find fexofenadine as a
substrate of numerous uptake and efflux transporters located on the apical and basolateral
membranes of intestinal epithelial cells, the possibility arises that the unknown
transporter(s) actually represent the major pathway for oral absorption and modulation by
fruit juices. We also showed that while GFJ significantly inhibited the activity of all
tested fexofenadine transporters, AJ only elicited inhibitory effects on OATP1A2mediated drug uptake, signifying a differential effect of fruit juices in vitro. However, it
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is well established that clinically, both GFJ and AJ are capable of mediating the FJDI, if
not to a greater extent by AJ. This disconnect between in vitro and in vivo findings
suggest that AJ may interact with unknown fexofenadine transporters to mediate its effect
on drug exposure. Future studies should therefore be conducted to identify these
unrecognized membrane proteins. For instance, a functional cloning approach which
involves a process of RNA fractionation followed by heterologous expression and
evaluation of fexofenadine transport activity may be used to discover novel transporters.
Another strategy would be large scale cloning of candidate solute carriers expressed in
the intestine based on human genome data and known cDNA sequences, followed by in
vitro characterization of fexofenadine transport activity. Finally, a genome-wide
association study examining individuals with unusually low and high fexofenadine levels
is a human genetic approach to identifying unknown fexofenadine transport proteins.

5.4.4

What are the Other Fruit Juice Constituents that Act as In
Vivo Modulators of Fexofenadine Absorption?

While we have some knowledge of the fruit juice constituents responsible for eliciting
transporter mediated-FJDIs, most studies have examined the effects of single flavonoids
on individual transport protein activity in vitro. This however, does not reflect the
collective effect of each flavonoid on the complement of intestinal transporters in vivo.
For instance, quercetin has been shown to inhibit the activities of OATP2B1 and OCT1
in cellular models. However, a human pharmacokinetic study revealed that quercetin coadministration resulted in an increase in fexofenadine exposure, a result that is opposite
to what in vitro data would suggest. This demonstrated that although quercetin has an
clear effect on in vitro drug transport, it does not decisively contribute to the effect in
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vivo (Kim et al., 2009). Consequently, there is a need to better characterize the essential
fruit juice components involved in transporter mediated FJDIs. This may be
accomplished by conducting clinical fexofenadine pharmacokinetic interaction studies
with individual flavonoids similar to those performed by Bailey et al. (2007) for naringin
and Kim et al. (2009) for quercetin.

5.5

Conclusions

FJDIs involving non-metabolized drugs are a cause of altered drug exposure leading to a
potential loss of therapeutic efficacy. Understandably, this food-drug effect has become a
growing concern for its impact on optimal patient therapy and safety. While several
transporter mediators have been proposed, the underlying mechanistic basis remains
unclear. The overall goal of this thesis was to elucidate the specific intestinal transporters
involved in this food-drug interaction. We found evidence for a growing complement of
intestinal fexofenadine transporters and the effect of fruit juices on their activity in vitro.
Moreover, we characterized mouse transporter orthologs of human intestinal
fexofenadine transport proteins as the groundwork for targeted studies in this rodent
model. In our experiments in mice, we found that this species does not recapitulate
human FJDIs. Finally, while mOatp2b1 appeared to be a potential mediator of FJDIs
based on convincing in vitro and gene expression results, we demonstrated using
Oatp2b1-/- mice that the transporter does not contribute to the effect in vivo. Overall,
while our results have not revealed that a single convincing mechanism exists, we have
provided evidence to suggest complex interactions among multiple intestinal transporters
with fruit juices is responsible for the observed pharmacokinetic interactions. We expect
that a better understanding of the precise mechanisms behind transporter mediated-FJDIs
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will allow for the provision of safer and more effective pharmacotherapy as well as allow
for more rational drug design.
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Appendix A: Transfection Validation
Methods
Transport Study
The success of HeLa cell transfection as determined by functional activity were evaluated
for mOatp1a1, mOatp1a4, mOatp1a6, OATP2B1, mOatp2b1 and mOct1 using transport
studies conducted according to methods outlined in Section 3.4.2 and by Cvetkovic et al.,
(1999). Greater uptake of well-established drug substrates, namely [3H]-estrone 3-sulfate
(E1S) for mOatp1a1 and mOatp1a4, [3H]-taurocholic acid (TCA) for mOatp1a6, [3H]rosuvastatin for OATP2B1 and mOatp2b1 and [14C]-tetraethylammonium (TEA) for
mOct1, by cells overexpressing these transporters versus control cells (transfection with
blank expression plasmids) validated transfection and served as positive controls for
transport function (Jonker et al., 2003; Ho et al., 2006; Gong et al., 2011; Tian et al.,
2015). In brief, the drug dose, which consisted of radiolabelled E1S, TCA, rosuvastatin or
TEA and their unlabeled drug (100 µM) dissolved in PBS when evaluating OATP2B1
and mOatp2b1 transport or KHB for all other transporters at pH 6 or pH 7.5 for mOct1,
was applied to cultured cells for 30 min at 37°C, 5% CO2. Subsequently, cells were
washed with ice-cold PBS, lysed and intracellular radioactivity was determined by liquid
scintillation spectrometry.
Immunofluorescence Microscopy
Another indicator of transfection success is the appropriate localization of protein. In the
HeLa cell model, mOatp2b1 is expected to be expressed in the plasma membrane in order
to facilitate intracellular drug accumulation. To validate localization, HeLa cells were

108

grown on 4-well culture slides (seeding density of 2.5 x 105 cells/well) at 37°C, 5% CO2
for 48 hours. Cells were transfected with blank expression plasmids (control) or
expression plasmids containing mOatp2b1 cDNA (1 µg DNA/well). After 48 hours, cells
were fixed with ice-cold 70% methanol in water (v/v) for at -20°C for 10 min.
Subsequently, 0.3% Triton X-100 in PBS (v/v) was used to permeabilize cells at RT and
blocking was performed using 2% bovine serum albumin in PBS (w/v) at RT for 30 min.
Cells were exposed to a custom-made rabbit polyclonal mOatp2b1 antibody (Invitrogen)
using a 1:200 dilution in PBS containing 0.05% v/v Tween-20 (PBST) at RT. At 1-hour
post incubation, cells were washed using PBST and subjected to Alexa Fluor 488 antirabbit secondary antibody (Invitrogen) using a 1:200 dilution in PBST at 37°C for 30
min. Following a final wash using PBST, cells were mounted using VECTASHIELD
Medium containing 4', 6-diamidino-2-phenylindole (DAPI) counterstain (Vector
Laboratories; Burlington, ON) and imaged by fluorescence microscopy (Nikon Eclipse;
Nikon Instruments Inc.; Melville, NY).
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Results
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Supplementary Figure 1. Transport of well established drug substrates by HeLa cells
expressing human and mouse intestinal uptake transporters. HeLa cells transiently
transfected with intestinal uptake transporters were evaluated for intracellular
accumulation of [3H]-estrone 3-sulfate (E1S), [3H]-taurocholic acid (TCA), [3H]rosuvastatin and [14C]-tetraethylammonium (TEA) (100 µM) at pH 6 or pH 7.5 for
mOct1 following a 30-minute incubation period. Data are expressed as percent of vector
control, mean ± SEM, n = 1 for mOatp1a6 and mOct1 and n = 2 for all other transporters.
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A

B

Supplementary Figure 2. Plasma membrane localization of mOatp2b1 as demonstrated
by immunofluorescence. HeLa cells transiently transfected with blank expression plasmid
as control (A) or mOatp2b1 expression plasmid (B) were stained with DAPI for nuclei
localization (blue) and Alexa Fluor 488 for mOatp2b1 localization (green).
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Appendix B: Identification of Fexofenadine Apical Efflux
Transporters
Methods
Transient transfection of HeLa cells was performed using Lipofectamine 3000 as
described in Section 3.4.1. Double transfections were performed where each efflux
transporter was expressed with an uptake transporter or blank plasmid at a 1:4 ratio of
uptake transporter/empty vector to efflux transporter (1 µg DNA/well total).
Fexofenadine transport studies were conduced as outlined by Section 3.4.2.
Results
To examine fexofenadine transport activity by human apical efflux transporters, a dual
overexpression system was used where each efflux transporter was expressed in the
presence and absence of human OATP1A2. OATP1A2 was used to drive fexofenadine
into cultured HeLa cells to allow for modulation of drug accumulation by P-gp, BCRP
and MRP2 mediated efflux. A reduction in cellular fexofenadine levels in cells that coexpressed both OATP1A2 and an efflux transporter when compared to cells only
expressing OATP1A2 would indicate fexofenadine transport by the expressed efflux
protein. We found that fexofenadine is a substrate of P-gp and MRP2 and perhaps BCRP,
in agreement with the literature (Supplementary Figure 3) (Cvetkovic et al., 1999;
Akamine et al., 2010; Ming et al., 2011). However, no strong conclusions can be made
from these results and no statistical analysis was performed as the efflux transport
experiment was conducted on one occasion (n = 1) with technical replicates.

[3H]-Fexofenadine Uptake
(% Vector Control)
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Supplementary Figure 3. Fexofenadine transport by HeLa cells expressing human
intestinal apical efflux transporters. HeLa cells transiently transfected with OATP1A2
and/or human apically localized efflux transporters were evaluated for intracellular
accumulation of [3H]-fexofenadine (0.1 µM) at pH 6 following a 30-minute incubation
period. The presence (+) or absence (-) of transporter expression in HeLa cells is shown
below and data are expressed as percent of vector control, mean ± SEM of triplicates (n =
1).
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Appendix C: Expression of Fexofenadine Transporters in
Mouse Small Intestine
Methods
Liver, kidney and small intestinal mucosa (scraped from the duodenum, jejunum and
ileum) were harvested from C57BL/6, Oatp2b1-/-, CF-1 and Mdr1a-/- mice, placed in
TRIzol Reagent (Thermo Fisher Scientific) and stored at -20oC until RNA extraction.
Tissues were homogenized and total RNA was isolated according to manufacturer’s
instructions (TRIzol). cDNA was synthesized from 2 µg total RNA by MultiScribe
Reverse Transcriptase with random hexamer primers (Thermo Fisher Scientific). SYBR
green-based (Thermo Fisher Scientific) qPCR (Applied Biosystems ViiA 7) was
performed using generated cDNA to determine the relative mRNA expression of mouse
uptake and efflux transporters using primers listed in Supplementary Table 1.
Transporter expression was normalized to 18S ribosomal RNA (TaqMan-based qPCR)
(Thermo Fisher Scientific). Analyses were performed in triplicates per transporter per
tissue and relative gene expression was calculated by the ΔΔCT method.
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Supplementary Table 1. Primer sequences for qPCR.
Gene

Forward Primer

Reverse Primer

mOatp1a1

5'-ACTCCCATAATGCCCTTGG-3’

5’-TAATCGGGCCAACAATCTTC-3’

mOatp1a4

5’-CCCAGAGCTCTCCAGTTTTG-3’

5’-TCCCATGTTGTTCTTCTGATTG-3’

mOatp2b1

5’-CTTCATCTCAGAACCATACC-3’

5’-ACTGGAACAGCTGCCATTG-3’

mOct1

5’-GGGTGTACGACACTCCCG-3’

5’-GCCCAAGTTCACACAGGACT-3’

Mdr1a

5’-CTCTTTGACTCGGGAGCAGAA-3’

5’-CGGAAACAAGCAGCATAAGAAA-3’

mMrp2

5’-CTGAGTGCTTGGACCAGTGA-3’

5’-CAAAGTCTGGGGGAGTGTGT-3’

mOstα

5’-TACAAGAACACCCTTTGCCC-3’

5’-CGAGGAATCCAGAGACCAAA-3’

mOstβ

5’-GTATTTTCGTGCAGAAGATGCG-3’

5’-TTTCTGTTTGCCAGGATGCTC-3’
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Results
In Section 4.3, we demonstrated that several mouse orthologs of human intestinal
transporters are functional in vitro fexofenadine transport proteins and are subject to
inhibition by fruit juices. To understand the potential relevance of these findings to in
vivo FJDIs, expression of these transporters in the mouse small intestine must be
confirmed in the mouse strains used in our experiments. Therefore, by qPCR, we
examined the mRNA expression of mouse fexofenadine transporters in mucosal
scrapings from various sections of the small bowel of all mouse strains (CF-1, Mdr1a-/[CF-1 background], C57BL/6 and Oatp2b1-/- [C57BL/6 background]) used in subsequent
in vivo fruit juice-fexofenadine interaction experiments. Intestinal expression of
transporters was compared to liver and kidney. Analyses were conducted in triplicate
with one mouse tissue sample per mouse strain.
In accordance with reports by Cheng et al. (2005) and Fu et al. (2016), the fexofenadine
transporters mOatp1a1 and mOatp1a4 were not expressed along the small intestine of all
4 mouse strains. Consequently, these results rule out these mouse Oatp1a transporters as
mediators of a fruit juice-fexofenadine effect in this species. Analogous to its human
ortholog, there was intestinal expression of mOatp2b1 in CF-1, Mdr1a-/- and C57BL/6
mice. As expected, mOatp2b1 mRNA was not detected in the Oatp2b1-/- mouse. mOct1
mRNA was expressed across all small intestinal sections as was recently reported by Fu
et al. (2016) (Supplementary Figure 4).
Mdr1a was expressed in all intestinal mucosa sections, with the exception of Mdr1a-/mice as expected. mMrp2 and mOstα was detected along the small intestine across all
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strains. Finally, with the exception of the CF-1 duodenum, mOstβ was expressed in all
small intestinal mucosa sections in all strains of mice (Supplementary Figure 5).
Overall, our expression results agree with the current literature. The combination of in
vitro transport activity and inhibitory profiles by fruit juices, together with gene
expression findings predict that mOatp2b1 and mOct1 could mediate a fruit juicefexofenadine interaction in mice.
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Supplementary Figure 4. mRNA expression of fexofenadine uptake transporters in
mouse small intestine. Gene expression of uptake transporters was measured by real-time
PCR in liver, kidney, and mucosal scrapings of the duodenum, jejunum and ileum of CF1 (wild-type) and its corresponding knockout mouse Mdr1a-/- and C57BL/6 (wild-type)
and its corresponding knockout mouse Oatp2b1-/-. Values are relative to CF-1 liver and
data are presented as mean ± SEM of triplicates, n = 1 per strain.
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Supplementary Figure 5. mRNA expression of fexofenadine efflux transporters in
mouse small intestine. Gene expression of efflux transporters was measured by real-time
PCR in liver, kidney, and mucosal scrapings of the duodenum, jejunum and ileum of CF1 (wild-type) and its corresponding knockout mouse Mdr1a-/- and C57BL/6 (wild-type)
and its corresponding knockout mouse Oatp2b1-/-. Values are relative to CF-1 liver and
data are presented as mean ± SEM of triplicates, n = 1 per strain.

119

Appendix D: Animal Use Protocol Approval

2014-012::1:
AUP Number: 2014-012
AUP Title: Interaction of medications and diet in Oatp1b2 KO animals
Yearly Renewal Date: 07/01/2015
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2014-012 has been approved,
and will be approved for one year following the above review date.
1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the ACVS
office. Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this
protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional safety
standards and have received all necessary approvals. Please consult directly with your institutional
safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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